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1 Summary 
1.1 English Summary 
Malignant melanoma is a very aggressive tumor with a high metastatic potential and 
persistently increasing incidence rate. The low efficacy of conventional chemotherapy and 
radiation demands for the development of new approaches. Several new strategies take 
advantage of the strong intrinsic immunogenicity of the tumor that in principle allows 
autologous Natural killer (NK) cells and T cells to recognize and kill melanoma cells. One of 
the key receptors involved in the anti-tumor immunity is NKG2D, expressed on NK cells and 
CD8+ T cells. So far, eight surface ligands for this receptor have been identified in humans, 
belonging to the MIC and ULBP molecule families. Interaction of NKG2D with its surface 
ligands activates and costimulates the cytotoxic activity of NK cells and T cells, respectively. 
Expression of NKG2D ligands (NKG2DL) is known to be induced upon cell stress and 
moderate expression of NKG2DL can also be observed on tumor cells. Thus developing 
strategies that induce NKG2DL expression on tumor cells might be helpful to enhance anti-
tumor immune responses, but as a prerequisite the mechanisms of NKG2DL regulation have 
to be elucidated. 
Proteasome inhibition causes so-called proteotoxic stress by an accumulation of 
unfolded proteins in the cell. As proteasome inhibitors are currently tested in melanoma 
therapy, the aim of the present study was to identify the impact of proteasome inhibition on 
NKG2DL expression in human melanoma cells. It was observed that treatment with the 
proteasome inhibitor MG132 strongly up-regulated the surface expression of the NKG2DL 
MICB on melanoma cells. Inhibitor treated cells contained elevated levels of MICB mRNA. 
MICB promoter driven luciferase reporter gene assays demonstrated that this up-regulation 
was dependent on transcription. Mutation of a heat shock factor 1 (HSF1) binding site within 
the MICB promoter region abrogated induction of transcription by MG132. Indeed, an 
enhanced binding of HSF1 to the MICB promoter in MG132 treated cells was demonstrated 
by chromatin immunoprecipitation (ChIP). Moreover, transfection of melanoma cells with a 
constitutively active HSF1 variant strongly stimulated MICB promoter driven reporter gene 
expression, whereas siRNA-mediated down-regulation of HSF1 blocked MICB induction 
upon proteasome inhibition.  
Interestingly, while over-expression of constitutive active HSF1 in the melanoma cells 
stimulated MICB promoter driven reporter gene expression, it did not enhance the 
transcription of endogenous MICB in melanoma cells, suggesting that under “normal 
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conditions” HSF1 could not efficiently access the MICB promoter. Ubiquitination of histone 
H2A is known as an epigenetic mechanism of gene silencing. ChIP experiments demonstrated 
that ubiquitinated histone H2A is associated with the MICB promoter and that treatment of 
melanoma cells with MG132 resulted in a loss of H2A ubiquitination. This leads to the 
conclusion that proteasome inhibition elicits MICB expression by two events: down-
regulation of the ubiquitination level of H2A, which controls promoter accessibility, and 
activation of HSF1 which then binds the MICB promoter and induces its transcription.  
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1.2 Deutsche Zusammenfassung 
Das maligne Melanom ist ein sehr aggressiver Tumor mit hohem Potential zur 
Metastasierung und stetig steigender Inzidenz. Die geringe Effizienz konventioneller Chemo- 
und Strahlentherapien verlangt nach der Entwicklung alternativer Behandlungsstrategien. 
Verschiedene neue Ansätze machen sich die hohe intrinsiche Immunogenität des Tumors zu 
Nutze, die es autologen Natürlichen Killer (NK) Zellen und T Zellen in Prinzip erlaubt, 
Melanomzellen zu erkennen und zu töten. Ein “Schüssel”-Rezeptor in der anti-Tumor 
Immunität ist NKG2D, der auf NK Zellen und CD8+ T Zellen exprimiert wird. Bislang 
wurden acht Oberflächenliganden dieses Rezeptors im Menschen identifiziert, die zur Familie 
der MIC oder ULBP Familie gehören. Die Interaktion von NKG2D mit seinen 
Oberflächenliganden aktiviert bzw. kostimuliert die zytotoxische Aktivität von NK Zellen und 
T Zellen. Die Expression von NKG2D Liganden (NKG2DL) wird bekanntermaßen durch 
Zellstress induziert und eine moderate NKG2DL Expression kann auch auf Tumorzellen 
beobachtet werden. Folglich könnten Strategien, welche die Expression der Liganden auf 
Tumorzellen induzieren, hilfreich sein, um anti-Tumor Immunantworten zu verstärken. Als 
Voraussetzung hierfür müssen jedoch die Mechanismen der NKG2DL Regulation aufgeklärt 
werden. 
Die Inhibition des Proteasoms verursacht durch die Akkumulation von ungefalteten 
Proteinen sogenannten proteotoxischen Stress in der Zelle. Da Proteasominhibitoren derzeit in 
der Melanomtherapie getestet werden, war das Ziel der vorliegenden Arbeit den Einfluss der 
Proteasominhibition auf die NKG2DL Expression in humanen Melanomzellen zu 
untersuchen. Es wurde beobachtet, dass die Behandlung mit dem Proteasominhibitor MG132 
zu einer starken Hochregulation der Oberflächenexpression des Liganden MICB auf 
Melanomzellen führte. Inhibitor behandelte Zellen enthielten erhöhte Mengen an MICB 
mRNA. MICB promoter-getriebene Luziferase-Reportergen Analysen ergaben, dass die 
Hochregulation in Abhängigkeit von der Transkription erfolgte. Durch die Mutation einer 
Hitzeschock Faktor 1 (HSF1) Bindungsstelle in der MICB Promoterregion wurde die 
Induktion der Transkription durch MG132 aufgehoben. Tatsächlich konnte eine verstärkte 
Bindung von HSF1 an den MICB Promoter in MG132 behandelten Zellen mittels Chromatin-
Immunpräzipitation (ChIP) nachgewiesen werden. Zudem führte die Transfektion von 
Melanomzellen mit einer konstitutiv aktiven HSF1 Variante zur einer starken Stimulierung 
der MICB Promoter-getriebenen Reportergen Expression, wohingegen durch die siRNA-
vermittelte Herabregulation von HSF1 die MICB Induktion unter Inhibition des Proteasoms 
aufgehoben wurde. 
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Während die Überexpression von konstitutiv aktivem HSF1 in Melanomzellen die ICB 
Promoter-getriebene Reportergen Expression stimuliert, konnte keine verstärkte Transkription 
von endogenem MICB in Melanomzellen beobachtet werden. Dies führte zu der Annahme, 
dass unter “normalen Bedingungen” ein effizienter Zugang von HSF1 zum MICB Promoter 
nicht möglich ist. Die Ubiquitinierung von Histon H2A ist bekannt als ein epigenetischer 
Mechanismus, der Gene abschaltet. ChIP Experimente zeigten, dass ubiquitiniertes Histon 
H2A mit dem MICB Promotor assoziiert ist und dass die Behandlung von Melanomzellen mit 
MG132 zu einem Verlust der H2A Ubiquitinierung führte. Dies führt zu der 
Schlussfolgerung, dass die Inhibition des Proteasoms die Expression von MICB über zwei 
Ereignisse steuert: die Herabregulation des Ubiquitinierung von H2A, welche den Zugang 
zum Promoter kontrolliert, und die Aktivierung von HSF1, welches dann an den MICB 
Promotor bindet und die Transkription induziert. 
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2 Introduction 
2.1 Melanoma epidemiology and conventional treatment strategies 
Malignant melanoma is a very aggressive metastatic tumor originating from 
melanocytes, the cells that produce the pigment melanin that colors skin, hair and eyes. 
Melanoma incidence has been growing rapidly in the last decades (Lee, 2010). The tumor is 
characterized by a high metastatic potential and according to Quintana et al. even a single 
melanoma cell is able to form a tumor in NOD/SCID mice (Quintana et al., 2008). The 5-year 
survival rate for patients with resectable melanoma is nearly 100 %. However, for patients 
diagnosed with advanced disease involving distant metastases only 10–15% can overcome the 
5 year-survival (Agarwala et al., 2010). Treatment options for such patients are few and 
mostly ineffective. Although, most patients receive systemic chemotherapy for metastatic 
disease, no therapeutic regimen has been shown to prolong survival in large, randomized, 
phase III trials. Dacarbazine (DTIC) treatment induces partial response rates of 10–13 % and 
complete responses of only 5 %. It has been used as a single-agent chemotherapy treatment 
for advanced melanoma for over 20 years (Eigentler et al., 2003). Temozolomide (TMZ), a 
functional analogue of DTIC, is well tolerated and is capable to penetrate into the central 
nervous system, which is essential for patients with brain metastases. However TMZ shows 
response and survival rates equivalent to DITC (Danson et al., 2003). The generally poor 
efficacy of all current single-agent chemotherapeutic approaches prompted numerous new 
studies encompassing combinations of chemotherapy, biochemotherapy and tumor specific 
immunological therapy (Eigentler et al., 2003; Gogas et al., 2007). 
2.2 Oncogenic signaling and targeted therapies in melanoma 
Significant attention has recently been focused on the development of targeted therapies 
that aim to selectively shut down the aberrant signaling pathways caused by genetic 
alterations that promote tumor formation, proliferation and therapy resistance. A number of 
mutations causing or accompanying melanoma development have been described (Chin et al., 
2006; Haluska et al., 2006; Dahl and Guldberg, 2007; Hocker et al., 2008). Mutations in the 
RAS-RAF-MEK-ERK signaling pathway are common for melanoma (Fig. 1). Of the tumors, 
20 % show activating mutations in NRAS, a GTPase and upstream member of the mitogen 
activated protein kinase (MAPK) signaling pathway, which can also stimulate the 
phosphatidylinosytol 3-kinase (PI3K) signaling pathway. The most common mutation found 
in about 70 % of malignant melanoma is a single amino acid substitution (V600E) in the B-
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RAF proto-oncogene, a serine/threonine-protein kinase, the downstream effector of RAS that 
activates the MEK kinase, which in turn activates ERK. Although, the targeting of the RAS-
RAF-MEK-ERK signaling pathway in vitro led to significant reduction of cell proliferation, 
in vivo experiments did not yield rewarding results (Panka et al., 2006).  
 
 
Figure 1. Melanoma signaling networks 
Simplified presentation of three of the major genetic networks involved in melanoma 
tumorogenesis, survival, and senescence. Included in the NRAS signaling network (green) are the 
MAPK and the PI3K/AKT pathways, which have been implicated in melanoma proliferation, survival, 
and progression. The CDKN2A locus encodes two separate tumor suppressors, p16 and p14ARF; both 
are thought to contribute to senescence and tumor growth restriction. The p53/Bcl-2 signaling network 
(red) is a major contributor to melanoma apoptosis and chemosensitivity and is regulated by many of 
the oncogenic melanoma pathways. Shown at the top of the figure are selected therapeutic agents that 
target each of these genetic networks (obtained from Hocker et al., 2008). 
 
Interestingly, the BRAF V600E mutation has been found frequently in benign and 
dysplastic nevi suggesting that this mutation represents an early event in melanocytic 
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neoplasia and alone is not sufficient for tumor formation. Thus, the full oncogenic potential 
depends on the presence of additional mutations leading to p53 inactivation or PTEN, INK4A 
deletion. MAPK signaling pathway has been found to be altered in about 90 % of melanoma, 
pointing out its essential role in melanocyte transformation (Bloethner et al., 2005; Chin et al., 
2006).  
The PI3K-AKT signaling pathway has been shown to be changed in up to 50 – 60 % of 
malignant melanoma (Aziz et al., 2007). It can be activated upstream by constitutively active 
NRAS, c-KIT or via inactivation of PTEN, which is known to block AKT activation (Fig. 1). 
The PI3K signaling pathway primarily acts via activation of the AKT kinase. Once activated, 
AKT has several different substrates, including Mdm2, procaspase 9, NF-κB, mammalian 
target of rapamycin (mTOR), and p27, many of which contribute to tumor proliferation and 
survival (Hocker et al., 2008).  
For malignant transformation alterations of genes the products of which are involved in 
pathways controlling cell cycle and senescence such as p16INK4A and p14ARF, both encoded by 
the major human melanoma genetic susceptibility locus CDKN2A via alternative reading 
frames, seem to be essential (Mooi and Peeper, 2006). Somatic alterations in cell cycle 
inhibitor genes in melanoma and some other tumors include mutations, homozygous deletions 
and promoter methylation. Germ-line mutations in the CDKN2A gene have been found to 
predispose carriers in melanoma-prone families to an increased risk of pancreatic cancer 
(Bloethner et al., 2006).  
Inhibition of overlapping pathways by small therapeutic inhibitors, such as the MAPK 
and PI3K-AKT signaling pathway, might be a promising strategy for melanoma treatment 
(Molhoek et al., 2005; Meier et al., 2007). Besides, also inhibitors of the proteasome, the 
major proteolytic machinery of the cell, are currently tested for their therapeutic capacity in 
tumor patients. Due to their high protein turnover, survival and growth of the tumor cells are 
essentially dependent on the activity of the proteasome (see below). 
2.3 The ubiquitin-proteasome system 
In living cells a huge number of proteins have to be synthesized, processed and 
degraded to maintain the normal function of the cell. Protein degradation occurs in different 
cellular compartments such as the cytosol, lysosome and endoplasmic reticulum. The majority 
of cytosolic protein degradation in eukaryotes is performed via the ubiquitin-proteasome 
system (UPS). The proteasome is a giant cytosolic protease located in the cytoplasm and 
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nucleus of eukaryotic cells. For proteasome-dependent degradation proteins are tagged by 
multimers of an evolutionarily conserved protein known as ubiquitin (Nandi et al., 2006). 
The functionally active 26S proteasome consists of a 20S core catalytic cylindrical 
complex capped at both ends by 19S regulatory subunits (Fig. 2). The 20S core proteasome is 
a complex of 28 protein subunits that are organized into four stacked rings and a cylindrical 
structure. The top and bottom rings of the 20S proteasome are formed by seven polypeptides, 
termed α-subunits. The two inner rings consist of seven β-subunits that form a central groove, 
which contains enzymatically active sites of the proteasome complex. Three (β1, β2 and β5) 
of the seven β-subunits have enzymatic activities, which have been characterized as 
chymotrypsin-like, trypsin-like and post-glutamyl peptidyl hydrolytic-like activities (Unno et 
al., 2002). A complex network of allosteric interactions regulates the sequence of enzymatic 
activities within the proteasome, which ultimately yields oligopeptides. The proteasome 
identifies proteins that have been targeted for degradation by their polyubiquitin “tag”, 
although ubiquitination is not a prerequisite for degradation of every protein (Pickart and 
Cohen, 2004). The 26S proteasome degrades proteins in an ATP-dependent manner. ATP 
hydrolysis is needed both for the formation of the 26S complex and for the unfolding and 
linearizing of large proteins to facilitate their entry into the catalytic inner core of the 
proteasome (Adams, 2004).  
The UPS plays a key role in protein destruction, but it is also directly or indirectly 
implicated in many important cellular processes such as cell cycle control, DNA repair, 
regulation of transcription, signal transduction, antigen presentation, stress responses and 
apoptosis (Fig. 2; Adams et al., 2004). The UPS is known to control cell cycle progression via 
turnover of cyclins, ubiquitinated short lived regulators of cyclin-dependent kinase 
complexes. The UPS is also involved in the DNA damage response pathway by influencing 
p53 protein stability. The negative regulator of p53 MDM2 is an ubiquitin-ligase, which 
ubiquitinates p53, targeting it for the degradation by proteasome. Another important aspect of 
proteasome function, related to the immune system, is the generation of peptides upon protein 
degradation, which are further processed by cytoplasmic and ER-resident peptidases and 
loaded into MHC class I molecules for presentation on the cell surface (Borissenko and Groll, 
2007).  
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Figure 2. Proteasome biogenesis and function 
Upper line: The seven α-subunits and seven β-subunits are assembled in one half-proteasome 
precursor. Dimerization of two precursor complexes leads to the formation of the 20S proteasome 
assisted by UMP1 a dedicated chaperone, which function is to “underpin the maturation of the 
proteasome” and is later degraded by the proteasome. To finalize the proteasome assembly the 19S lid 
is attached to the top and bottom of the 20S complex, forming the fully functional proteolytic 
complex. 
Bottom line: Substrates dedicated to digestion such as misfolded, unfolded or damaged proteins, 
short lived proteins, undergo polyubiquitination interacting with ubiquitin ligases (E1-3), are degraded 
by the proteasome to small peptides and further processed for the presentation by MHC class I 
molecules or cut into amino acids for reuse in protein synthesis (obtained from Dohment R.J., Inst. for 
Genetics, University of Cologne). 
 
2.4 Proteasome inhibitors in tumor therapy 
Proteasome inhibitors originally used for the study of proteasome function appear to be 
cytotoxic for rapidly proliferating cells e.g. tumor cells, while less affecting quiescent cells. A 
possible explanation for this phenomenon could be that malignant cells due to their high 
proliferation rate accumulate damaged proteins, and therefore show a higher dependency on 
the proteasomal degradation processes (Almond and Cohen, 2002). Proteasome inhibitors 
tested in vitro on multiple myeloma, breast cancer and melanoma cells increased cell death 
(Chauhan et al., 2005; Ames et al., 2008; Młynarczuk-Biały et al., 2006; Lecis et al., 2010). 
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Nowadays proteasome inhibitors are intensively tested in the clinic in anti-cancer therapy 
either as monotherapy or in combination with other chemotherapeutic agents. Recently, the 
proteasome inhibitor bortezomib/PS-431 (Velcade) has been approved by the U.S. Food and 
Drug Administration (FDA) for the treatment of relapsed/refractory multiple myeloma. The 
mechanism of bortezomib action is still under the investigation, but it is known that 
bortezomib induces apoptosis in multiple myeloma cells via a number of different 
mechanisms (Chauhan et al., 2005; Obeng et al., 2006). In vitro studies have demonstrated 
that bortezomib attenuates NF-κB prosurvival activity by blocking proteasome degradation of 
IκB, an inhibitory subunit of the inactive NF-κB complex. Bortezomib-induced apoptosis has 
also been shown to be associated with following additional events: activation of stress 
response proteins such as heat shock proteins Hsp27, Hsp70, and Hsp90; up-regulation of the 
c-jun kinase; alteration of the mitochondrial membrane potential and production of reactive 
oxygen species; induction of the intrinsic cell death pathway and activation of extrinsic 
apoptotic signaling; impairment of the DNA repair machinery via inactivation of the DNA-
dependent protein kinase; and down-regulation of mitogen-activated protein kinase and 
PI3K/Akt signaling pathways; phosphorylation and activation of p53. Taken together, these 
signaling events may collectively contribute to the overall anti-multiple myeloma activity of 
bortezomib against multiple myeloma (Chauhan et al., 2005). 
In contrast to hematological malignancies, treatment of solid tumors with proteasome 
inhibitors as monotherapy was less successful, although in vitro tests showed promising 
results. bortezomib has been applied to non-small cell lung cancer and breast cancer patients 
in combination with other chemotherapeutical agents to sensitize tumor cells toward 
chemotherapeutic drugs (Lara et at., 2006; Ames et al., 2008). For melanoma, treatment with 
the combination of paclitaxel, carboplatin and proteasome inhibitor bortezomib showed 
limited efficacy in a phase II trial (Croghan et al., 2010). So far, proteasome inhibitors have 
only been considered as drugs to induce apoptosis. However, along with the inhibition of 
tumor cell proliferation may sensitize the cancer cells to the NK-mediated elimination, as 
demonstrated for multiple myeloma and hepatocellular carcinoma cells (Armeanu et al., 
2008). Furthermore, in vitro treatment of melanoma cells with proteasome inhibitors has been 
demonstrated to increase the sensitivity of tumor cells to adoptive T-cell attack (Seeger et al., 
2010). The immunological effects of proteasome inhibition might be exploited by 
immunotherapy. 
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2.5 Immunotherapy of malignant melanoma 
Immunotherapy of malignant melanoma is aimed at increasing of the effectiveness of 
anti-tumor immune responses by a number of different approaches such as vaccination or 
adoptive cell transfer. However, strategies dedicated to abrogate immune-suppression are 
followed such as the therapy with monoclonal antibodies targeting the cytotoxic T-
lymphocyte antigen 4 (CTLA-4), a molecule triggering T cell tolerance (Schadendorf et al., 
2009).  
During the last decade a number of melanoma vaccines have been developed based on 
the growing body of knowledge of tumor antigens and their peptide epitopes. So far, two main 
directions in therapeutic vaccination have been followed: vaccination with peptides and 
peptide-loaded dendritic cells. Unfortunately, these vaccination strategies have been shown to 
be ineffective in patients with distant metastatic melanoma (Schadendorf et al., 2009).  
Adoptive cell transfer (ACT) exploits the observation that melanoma cells can be 
effectively recognized and eliminated by antigen-specific CD8+ T cells. Over the last two 
decades a number of melanoma-associated T cell antigens have been identified. Via their T 
cell receptor CD8+ T cells recognize peptide epitopes derived from these antigens in the 
complex with MHC class I molecules. The ACT approach is based on the ex vivo activation 
and expansion of autologous T lymphocytes and their re-infusion back to the patient (Yee et 
al., 2002; Dudley et al., 2002; Straten and Becker, 2009). Recently, ACT therapies based on 
the adoptive transfer of Melan-A/MART-1 or gp100 antigen-specific CD8+ T cell clones 
obtained from peripheral blood of melanoma patients, have been tested (Khammari et al., 
2009; Mackensen et al., 2006). In contrast to chemotherapy, ACT is well tolerated and the 
main adverse effects were mainly related to the injection of cytokines applied under the 
therapy. Significant clinical efficacy and diminished side effects make the ACT one of the 
most promising strategies in the melanoma therapy emerging recently (Straten and Becker, 
2009). However, a main obstacle that may interfere with efficient melanoma cell recognition 
and eradication is the development of tumor immune escape variants. Down-regulation or 
complete loss of surface MHC class I molecules is a well-known mechanism of tumor cells to 
escape the MHC restricted T cell surveillance (Paschen et al., 2006). Nevertheless, such cells 
should still be recognized and eliminated by the innate immune system in particular by 
Natural Killer (NK) cells, as described below. Recently, some studies utilizing NK cells for 
metastatic melanoma treatment have been started (Burke et al., 2010).  
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2.6 NK cells and their receptors 
Natural killer (NK) cells are lymphocytes of the innate immune system comprising 
about 10% of the peripheral blood lymphocytes. They monitor autologous cells for an 
aberrant expression of surface MHC class I molecules or stress markers. MHC class I positive 
“healthy” autologous cells are protected from NK cytotoxicity.  
NK cells are characterized by a strong cytolytic activity against virus-infected cells and 
malignant cells. Upon activation NK cells can display an immunomodulating action via the 
production of cytokines such as TNF-α and IFN-γ or can directly kill target cells by releasing 
perforines and granzymes (Bryceson et al., 2006). The cytolytic activity of NK cells is tightly 
regulated by the balance of signals received from inhibitory and activating receptors. The NK 
inhibitory receptors fall into two main groups according to their structure and consist of 
immunoglobulin superfamily receptors including killer-cell immunoglobulin like receptors 
(KIR) and C-type lectin-domain receptors. Inhibitory receptors are sensors of “normal 
homeostasis” and bind to classical and non-classical MHC class I molecules (Vivier and 
Malissen, 2005), which in turn prevents the killing of normal cells. The down-regulation or 
the lack of MHC class I molecules on the target cell surface can serve as a signal of NK cell 
activation and is described by the “missing self” theory (Ljunggren et al., 1990). Recently it 
has been shown that for complete activation NK cells have to receive activating signals by 
receptors binding to corresponding surface ligands on the target cell (Mistry and O’Callaghan, 
2007). Activating receptors expressed on NK cells are structurally related to the inhibitory 
KIR and C-type lectin-domain receptor families, but there are also many unrelated receptors 
such as the natural cytotoxicity receptor family. The ligands for activating NK receptors are 
commonly not expressed by normal cells. Viral infection, or malignant transformation, or the 
presence of other stress conditions can lead to the up-regulation of activating ligands on the 
cell surface that renders them susceptible to NK cell-mediated lysis as described by the 
“altered self or stressed self” theory (Malarkannan, 2006). The inhibitory and activatory NK 
cell receptors discovered so far and their ligands are listed in Table 1 (Empson et al., 2010). 
One of the most well studied activating NK receptors is Natural-killer group 2, member 
D (NKG2D), which is known to be a key receptor in anti-tumor immunity. NKG2D is a 
dimeric, type II transmembrane protein, which in humans is constitutively expressed by 
natural killer (NK) cells, most NKT cells, subsets of γδ T cells, all CD8+ T cells, and a subset 
of CD4+ T cells (Champsaur and Lanier, 2010). This receptor directly activates NK cells and 
acts as a co-stimulatory receptor for T cells. The signaling activity of human NKG2D is 
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mediated through an exclusive interaction with the adaptor protein DAP10 (Coudert and Held, 
2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Inhibitory and activating NK cell receptors and their ligands 
(Adapted from Empson et al., 2010) 
2.6.1 The role of NKG2D and NKG2D ligands in tumor immune surveillance 
The critical role of NKG2D in the tumor surveillance has been shown in different mouse 
tumor models. For example, mice inoculated with MHC class I positive RMA lymphoma cells 
developed tumors while mice transplanted with RMA cells, recombinantly expressing the 
murine NKG2D ligand Rae-1 did not show tumor formation (Cerwenka et al., 2001). The 
significance of NKG2D in early tumor immune surveillance has recently been demonstrated 
by Guerra et al. in the NKG2D-deficient mouse model (Klrk1-/-) (Guerra et al., 2008). These 
mice do not show any disturbances in the embryonic development and exhibit no visible 
alterations in major organs. Klrk1-/- mice were further interbred with the well characterized 
mouse prostate adenocarcinoma model (TRAMP) in order to study the influence of the 
NKG2D knock-down on tumor development. The TRAMP-mice get mild to severe prostate 
hyperplasia by 12 weeks of age developing to the severe hyperplasia and adenocarcinoma by 
18 weeks of age and metastatic disease by 30 weeks of age. NKG2D-deficient TRAMP mice 
(Klrk1-/- TRAMP) displayed early-arising, massive prostate tumors progressing rapidly to 
poorly differentiated lesions, while their NKG2D positive littermates (Klrk1+/+ TRAMP) 
mostly developed late-arising carcinomas, which were classified as phylloides-like tumors, a 
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non malignant epithelial-stromal tumor. Moreover, early-arising large tumors in NKG2D-/- 
mice showed substantially higher amounts of NKG2D ligand transcripts and ligand surface 
expression as compared to large early-arising tumors of NKG2D+/+ littermates, suggesting 
that NKG2D-dependent immunoediting can favor loss of NKG2D ligands at the early stages 
of malignant tumors formation and disease aggressiveness. In case transgenic mice 
developing mixed pre-B and B-lymphomas (Eµ-myc mice) were inbred with NKG2D-/-
(Klrk1-/-) mice, the onset of the disease occurred significantly earlier in the B6-Klrk1-/-Eµ-myc 
mice than in B6-Klrk1+/+Eµ-myc mice, suggesting that NKG2D deficiency accelerates the 
progression of Eµ-myc driven lymphomas (Guerra et al., 2008).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Structures and affinities of human NKG2D ligands  
A. MICA and MICB are the only NKG2DL known to contain a α3-like domain, similar to 
classical MHC class I molecules, while all other ligands contain only α1 and α2 domains. NKG2DL 
can either be transmembrane proteins or GPI-anchored proteins. 
B. The affinities are expressed as the equilibrium dissociation constant (KD) and given for 
interactions between NKG2D receptor and ligands of the same species (adapted from Champsaur and 
Lanier, 2010). 
 
In humans eight ligands for the NKG2D receptor have been identified, which have a 
structure similar to classical MHC class I molecules (Fig.3). They fall into two families: the 
MHC class I chain related sequence A and B (MICA and MICB) group and the 
cytomegalovirus UL-16 binding protein (ULBP1 – 6) family (Champsaur and Lanier, 2010). 
All NKG2D ligands (NKG2DL) show structural similarity in their α1 and α2 extracellular 
domains to those of classical MHC class I molecules. However, the differences between the 
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two groups of NKG2DLs are rather significant. MICA and MICB are transmembrane proteins 
consisting of three extracellular domains, while ULBP molecules have two extracellular 
domains and are GPI-anchored in the cell membrane, except for ULBP4 and 5, which have 
been described to be transmembrane proteins (Mistry and O’Callaghan, 2007; Champsaur and 
Lanier, 2010). 
NKG2DL are highly polymorphic, particularly the MICA and MICB genes of which 70 
and 31 alleles have been described, respectively. In the last decade growing interest has been 
displayed to the regulation of NKG2DL expression. It has been demonstrated that viral 
infection induces expression of NKG2DL on the cell surface. Viral products could directly 
affect the transcription of NKG2DL or infection could indirectly promote ligand expression 
through the induction of cytokines. On the other hand, viruses such as human and mouse 
cytomegalovirus, HCMV and MCMV, respectively, evolved numerous mechanisms to evade 
NK cell recognition and in particular NKG2D-mediated immune surveillance via retention of 
activating ligands in the virus-infected cell (Champsaur and Lanier, 2010). 
Numerous studies revealed NKG2DL expression by different human tumor cell lines 
and freshly extracted primary tumors and demonstrated that expression of NKG2DL on 
tumors renders them susceptible to killing by NK cells in vitro. Although, surface expression 
of NKG2DL has been detected on a wide variety of tumors, the profile of the expressed 
molecules has been reported to be various. Jinushi et al. detected MICA and MICB expression 
on a subset of human hepatocellular carcinoma tissues. They also found that MIC molecules 
are involved in hepatoma cell sensitivity to NK cells (Jinushi1 et al., 2003). Hematological 
tumors such as different types of leukemia, including acute myeloid leukemia (AML), acute 
lymphatic leukemia (ALL), chronic myeloid leukemia (CML), and chronic lymphatic 
leukemia (CLL) have been shown to express heterogeneous levels both MIC and ULBP 
molecules, though a predominant expression of ULBP2 has been reported (Pende et al., 
2002). Salih et al. demonstrated that expression of NKG2DL accounted for the NK cell-
mediated lysis of AML and CML cells (Salih et al., 2003).  
2.6.2 Regulation of NKG2D ligand expression 
NKG2DL are rarely expressed on the surface of normal healthy cells (Eagle et al., 2009) 
and their expression is associated with cellular stress caused among others by tumorogenesis, 
though the transforming activity of tumor oncogenes like N-ras, c-myc, Akt, c-kit or their 
combinations, was not found to directly force NKG2DL expression (Nausch and Cerwenka, 
2008). At present, several stresses influencing NKG2DL expression both in normal and in 
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malignant cells have been identified. Studying the molecular mechanisms it has been shown 
that different stresses affect different signaling pathways and stimulate various NKG2DL 
expression pattern. NKG2DL have been shown to be regulated transcriptionally, post-
transcriptionally and post-translationally. The promoter region of MICA and MICB genes has 
been characterized and similar regulatory elements controlling their expression have been 
found (Eagle et al., 2006; Venkataraman et al., 2007). In tumor cells lines expressing MICs 
constitutively  occupied GC boxes (Sp1 binding sites) and an inverted CCAAT box have been 
shown to control MIC expression, though these elements are also believed to be responsible 
for stress-induced expression of MIC molecules in normal cells. A key element found both 
onto MICA and MICB promoter sequence, regulating MIC expression under heat shock and 
oxidative stress, is a heat shock responsive element (HSE) (Venkataraman et al., 2007). For 
ULBP molecules the main stress-responsive element has been found to be a NFκB binding 
site, while their expression in tumor cells is considered to be regulated by a complex of Sp1 
and Sp3 transcription factors (Eagle et al., 2006). 
NKG2DL have been shown to be regulated not only transcriptionally but also post-
transcriptionally. Stern-Ginossar et al. identified a group of endogenous cellular microRNAs 
(miRNAs) that bind to the 3’-UTR (untranslated region) of MICA and MICB and repress 
their translation thereby limiting the expression of the stress ligands under normal conditions 
(Stern-Ginossar et al., 2008). Tumor cells can also benefit from the down-regulation of stress 
ligands by onco-microRNAs and escape from the NK cell surveillance.  
A role of the BCR/ABL oncogene in the regulation of NKG2DL expression was 
discovered by Boissel et al. (Boissel et al., 2006). Constitutively active BCR/ABL fusion 
kinase in CML cells activates the PI3K/mTOR pathway, which in turn has been shown to 
affect MICA translation. Also the DNA damage pathway has been found to induce NKG2DL 
expression. Double strand brakes and stalled DNA replication are sensed by the PI3K-related 
protein kinases ATM (ataxia telangiectasia, mutated) and ATR (ATM and Rad3-related), 
respectively, which results in cell cycle arrest and DNA repair or in apoptosis if the DNA 
damage is too extensive to be repaired. DNA damage pathway has been shown to be 
constitutively active in certain human cancer cells. Gasser et al. demonstrated that both mouse 
and human cells up-regulate NKG2DL following treatment with DNA-damaging agents 
(Gasser et al., 2005). They proposed that this effect was dependent on ATR / ATM function, 
as inhibitors of ATR and ATM kinases prevented ligand up-regulation in a dose-dependent 
fashion. Moreover, ATR and ATM have been shown to stimulate NKG2DL expression 
independently of p53, though the exact molecular mechanism remains to be elucidated.  
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Furthermore, it has been shown that treatment with histone deacetylase (HDAC) 
inhibitors led to an up-regulation of MICA and MICB in hepatoma cells and in leukemic 
cells. This suggests that hypoacetylation of MIC promoters, associated with transcriptional 
silencing, was abrogated by the HDAC inhibitors Trichostatin A and Sodium valproate and 
resulted in an accumulation of hyperacetylated histones and an up-regulation of the repressed 
genes (Armeanu et al., 2005; Andersen et al., 2007; Kato et al., 2007). Besides, treatment of 
myeloma cells with proteasome inhibitors has been demonstrated to induce NKG2DL 
expression, however, the detailed underlying molecular mechanisms are still unknown 
(Jinushi et al., 2008). 
Toll-like receptor (TLR) signaling has been also shown to stimulate NKG2DL 
transcription. Peritoneal macrophages treated either with TLR agonists in vitro, or in vivo 
after the injection of LPS, exhibited surface expression of Rae-1, the murine NKG2DL 
(Hamerman et al., 2004). Poly(I:C) and LPS, which induced TLR signaling on dendritic cells 
(DC), also resulted in ULBP1 and ULBP2 ligand expression (Ebihara et al., 2007). Certain 
cytokines are also known to influence NKG2DL expression. IFN-α in humans leads to the 
expression of MICA on DC (Jinushi2 et al., 2003). However, other cytokines have been 
demonstrated to down-regulate NKG2DL expression. For instance, treatment of human 
melanoma cells with IFN-γ resulted in a decreased MICA expression (Schwinn et al., 2009). 
Interestingly, IFN-γ-regulated miRNAs have been discovered that can suppress MICA 
expression (Yadav et al., 2009). Transforming growth factor-β (TGF-β) has been also 
described to decrease the transcription of MICA, ULBP2 and ULPB4 in human malignant 
gliomas (Eisele et al., 2006). Thus, different signals exist that down-regulate NKG2DL 
expression thereby allowing tumor cells to escape from NKG2D-mediated immune 
surveillance. 
2.6.3 NKG2D ligands and immune escape 
Several mechanisms have been described by which tumors evade from NKG2D 
mediated immune surveillance (Champsaur and Lanier, 2010). One of the mechanisms is 
based on the shedding of NKG2DL from the cell surface. This impairs the recognition of the 
tumor cells by NK cells and decreases cell lysis (Salih et al., 2003; Waldauer et al., 2008). 
Moreover, shed soluble NKG2DL (sNKG2DL) which are detectable in the sera of tumor 
patients, are still able to bind to the NKG2D receptor on lymphocytes thereby inducing its 
internalization. Thus, sNKG2DL contribute to tumor immune escape. Our group 
demonstrated that elevated levels of soluble ULBP2 in the sera of melanoma patients correlate 
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with poor survival (Paschen et al., 2009). Therefore, understanding the regulation of 
NKG2DL expression in tumor cells will allow the design of novel therapeutical strategies to 
improve immune response in the patient.  
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2.7 Aims of the study 
Metastatic melanoma is one of the most aggressive tumors, characterized by an 
increasing incidence. The low efficacy of the conventional therapies demands for the 
development of new treatment approaches. Several strategies take advantage of the strong 
intrinsic immunogenicity of the tumor that in principle allows autologous NK cells and T cells 
to recognize and kill melanoma cells. An important lymphocyte receptor involved in tumor 
immune surveillance is NKG2D. Expression of its surface ligands the MIC and ULBP 
molecules is induced upon cell stress but can also be detected on tumor cells. Binding of 
NKG2D to the ligands on tumor cells strongly stimulates the cytotoxic anti-tumor activity of 
NK cells and co-stimulates T cell activity. Thus developing strategies to enhance NKG2D 
ligand expression on melanoma cells might be helpful to enhance tumor immunogenicity. 
Proteasome inhibition causes an accumulation of unfolded proteins in the cell, which 
should increase the expression of NKG2DL. As proteasome inhibitors are currently tested in 
melanoma therapy, the aim of the present study was to identify the impact of proteasome 
inhibition on NKG2DL expression in melanoma cells and to elucidate the underlying 
molecular mechanisms. 
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3 Materials and methods 
3.1 Materials 
Lab equipment        Company 
Autoclave Syntec 
Balance Kern 
Blotting cells BioRad 
Cassette for film development BioRad 
CO2 incubator Binder 
Cooling microcentrifuge Hermle 
Dark Hood BioStep 
Fastpette V-2 Labnet 
Gallios Cytometer Beckman Coulter 
Gradient thermocycler BioRad 
High speed Cooling centrifuge Rotanta 460R Hettich 
Horizontal electrophoresis System for agarose gels BioRad 
Infinite M200 Tecan 
Laminar flow hood ThermoScientific 
Microcentrifuge Biofuge 
Magnetstirrer IKA-Combimag RCT 
Microscope Leica 
Mini-PROTEAN Vertical electrophoresis System BioRad 
Mixer Ususio VTX-3000L Oehmen Lab Technik 
Multichannel pipette Rainin 
pH-meter 510 EUTECH Instruments 
Pipette set: 1000, 100 and 10 µl Rainin 
Rotamax 120 (Thermoblock) Heidolph Instruments 
Refrigerators: +4; -20; -80°C  
Shaker Rotamax 120 Heidolph Instruments 
Step One Plus real-time PCR system Applied Biosystems 
Waterbath Fischer & Rintelen 
 
Disposable and re-usable materials                Company 
6 well Plates TC TPP 
8er Strips PCR-tubes with single caps 0,2 ml Biozym 
96 Well Suspension culture Plate with lid sterile Greiner/Oehmen 
96 Well Plate flat bottom white Costar 
96 Well Multiply Fast PCR Platte Sarstedt 
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96 Well Half Area Microplatte UV-Star Transparent µclear Tecan 
Amersham Hyperfilm  ECL  18x24 cm GE Healthcare 
Amersham Hybond ECL  GE Healthcare 
Cell count chamber Neubauer 
Cell culture flasks 25 cm3; 75 cm3; 175 cm3 Greiner Bio-One 
Cell scraper 28 cm Greiner Bio-One 
Cover glass Neubauer 
Falcon tubes 15 ml; 50 ml Oehmen 
Filter 0,2 µm sterile  Sartorin  
Foam Pads 8x11 cm BioRad 
Freezing Tubes 2 ml, Greiner Oehmen 
High speed centrifuge plastic tubes 50 ml Nalgene 
Optical adhesive covers Applied Biosystems 
Petri dish m.N. 100/20mm TC Greiner Greiner Bio-One 
Petri dish m.N. 60/15mm TC Greiner Greiner Bio-One 
Pipette tips 10, 100, 1000 µl Rainin 
Reaction tubes, Safe lock 0,5; 1,5; 2,0 ml safe-lock  Eppendorf 
Syringe 5, 10, 50 ml sterile Terumo 
Tissue culture plates uncoated Greiner Bio-One 
Whatman-Papier 3MM Chr sheets 46x57 cm GE Healthcare 
 
Cell culture / media                 Company 
FCS Charge A10108-2367 PAA 
OptiMem Gibco 
PBS w/o Ca Mg (1x) Invitrogen 
Penicillin/Streptomycin 100x PAA 
RPMI 1640 mit L-Glutamin PAA 
Trypsin-EDTA (10x) PAA 
 
Kits                    Company 
ChIP IT Express Enzymatic Active Motif 
ChIP IT Express HT Active Motif 
ChIP IT Control Kit Human Active Motif 
DuaL-Glo Luciferase Assay System  Promega 
GeneJet Plasmid Miniprep Kit Fermentas 
One Shot TOP10 Chemically Competent E.coli Invitrogen 
pcDNA 3.1 V5-His TOPO TA Expression Kit Invitrogen 
Plasmid Maxiprep Kit Qiagen 
QiaAmpDNA Blood Mini Kit  Qiagen 
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Quick Change Lightning Mutagenesis Kit Stratagene 
QIAQuick Nucleotide Removal Kit Qiagen 
QiaQuick PCR Purification Kit Qiagen 
Qiashredder Qiagen 
Reporter Lysis Buffer 5x Promega 
Rnase-Free DNase Set Qiagen 
Rneasy Plus Mini Kit Qiagen 
 
Reagents / Chemicals                      Company 
Inhibitors 
Actinomycin D Sigma-Aldrich 
Brefeldin A Sigma-Aldrich 
Chloroquine Sigma-Aldrich 
Cycloheximide Sigma-Aldrich 
MG132(Z-leu-leu-leu-al) Sigma-Aldrich 
General 
Agarose Sigma-Aldrich 
Agar-agar Invitrogen 
Ampicillin Sigma-Aldrich 
Aqua ad iniectabilia  Braun 
Calcium chloride Sigma-Aldrich 
DMSO Sigma-Aldrich 
EDTA Sigma-Aldrich 
Ethanol p.A absolut Sigma-Aldrich 
Ethidiumbromid 1% Roth 
Formaldehyde 37% Merck 
Hepes Biochrom 
Isopropanol p.A. Sigma-Aldrich 
Kalium chlorid  Merck 
PMSF  Biochemica 
Sodium chlorid p.A Merck 
Sodium hydroxyde Fluka 
Trypanblue 0,5%  Biochrom 
Trypton/Pepton from Casein Roth 
Yeast extract Gerbu 
FACS 
APC-Annexin V BD Biosciences 
Propidium iodid BD Biosciences 
Flow Check Beckman Coulter 
COULTER CLENZ Cleaning Agent  Beckman Coulter 
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IsoFlow Sheath Fluid Beckman Coulter 
Western blot 
30% Acrylamid Bis solution BioRad 
β-mercaptoethanol Sigma-Aldrich 
Ammoniumperoxidsulfat Sigma-Aldrich 
Bradford Reagent Sigma-Aldrich 
Bromphenolblue Sigma-Aldrich 
BSA Type H1 Gerbu 
BSA Standard solution BioRad 
Complete Protease inhibitor tablet Roche 
Glycin Gerbu 
Glycerol Roth 
H2O2 p.A Merck 
Luminol Sigma-Aldrich 
Methanol Sigma-Aldrich 
Non fat dry milk Gerbu 
p-Coumarine acid Sigma-Aldrich 
PageRulerTM Prestained Protein Ladder Fermentas 
Puanceou Solution Sigma-Aldrich 
SDS  Gerbu 
Sodium deoxycholate Gerbu 
Tris Base AppliChem 
Triton-x-100 Sigma-Aldrich 
Temed Sigma-Aldrich 
Tween 20 Gerbu 
RT-PCR / quantitative RT-PCR / cloning 
Deoxynucleotide Mix 10mM Stratagene 
DNA loading dye (6 x) Fermentas 
DSF-Taq DNA polymerase 500u Bioron 
Expand High Fidelity PCR System Roche 
GeneRulerTM 100 bp DNA Ladder Plus Fermentas 
GeneRuler TM 1 kb DNA Ladder Fermentas 
High-Capacity cDNA Reverse Transcription Kits Applied Biosystems 
Hind III Fermentas 
Nco I Fermentas 
T4 DNA Ligase Promega 
TaqMan Universal PCR Master Mix, no AmpErase UNG Applied Biosystems 
Taqman Gene Expression Assay GAPDH (4352934E) Applied Biosystems 
Taqman Gene Expression Assay HSP70 
(Assay ID HS00271229-s1) Applied Biosystems 
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Thermoprime Plus ThermoScientific  
Yellow Tango buffer (10 x) Fermentas 
Transfection 
Fugene HD Roche 
X-Treme Gene siRNA transfection reagent Roche 
Chromatin immunoprecipitation 
Acid Phenol Chloroform Applied Biosystem 
Ethanol Sigma-Aldrich 
Sodium acetate Sigma-Aldrich 
 
Buffers and solutions 
Flow Cytometry: 
1) FACS buffer:   PBS (1 x)   500 ml 
     FCS    50 ml 
     NaN3     0.5g 
2) 10 x Binding buffer  Hepes     0.1 M (pH 7.4) 
     NaCl    1.4 M 
     CaCl2    25 mM 
3) Fixation solution (PFA):   4 % Formaldehyde in PBS  
Western blot: 
1) 10% SDS:     50 g SDS in 500 ml H2O 
2) 10% Ammoniumperoxidsulfat:  1 g in 10 ml H2O  
3) 0,25% Bromphenolblue:   50 mg in 202 ml H2O 
4) RIPA buffer for protein  Tris     50 mM 
    extraction     NaCl    150 mM 
SDS    0.1 % 
Na Deoxycholate  0.5 % 
Triton X 100    1 % 
PMSF    1 mM 
Roche Complete Protease inhibitor tablet 
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5) 5 x Sample buffer:   Glycerol (99%)  5 ml 
     SDS    1.5 g 
     0.25 % BPB   1 ml 
     adjust with H2O up to  7.5 ml 
     mercaptoethanol   2.5 ml 
6) 4 x low buffer:   Trisma Base 1,5M  90.85 g 
     10 %  SDS   20 ml 
     adjust with H2O up to  500 ml 
     pH 8.8 
7) 4 x upper buffer:   Trisma Base 0,5M   15.15 g 
     10 % SDS   10 ml 
     adjust with H2O up to  250 ml 
     pH 6.8 
8) 10 x running buffer:  Trisma Base     75 g 
(electrophoresis buffer)  SDS    25 g 
     Glycin    360 g 
     adjust with H2O up to  2500 ml 
9) 10 x transfer buffer:  Trisma Base    75 g 
     SDS    9.35 g 
     Glycin    362.5 g 
     adjust with H2O up to  2500 ml 
10) PBS/Tween (TBS):  2 ml Tween dissolve in 2000 ml PBS 
11) ECL-blots development: 
      Solution A   TRIS-HCl 0.1 M (pH 8.6)  200 ml 
     Luminol   50 mg 
      Solution B    p-Coumarin acid  11 mg 
     DMSO   10 ml 
Mix immediately before use:  
For 1 miniblot membrane (8 x 11 cm) 4 ml SA + 1.2 µl H2O2 + 400 µl SB 
Bacterial cultures 
1) LB-Medium:   Trypton/Pepton from Casein 10 g  
   Yeast extract   5 g 
   NaCl    10 g 
Adjust with water up to 1 l, autoclave 
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LBAmpicillin-Medium: LB-Medium plus sterile Ampicillin solution (150 µg/ml) 
2) Agar-plates:   Agar-Agar   12-14 g  
  Trypton/Pepton from Casein 10 g 
   Yeast extract   5 g 
   NaCl    10 g 
Adjust with water up to 1 l, autoclave 
Chromatin immunoprecipitation 
1) Ethanol 70% 
2) Sodium acetate 3M, pH 5.2 
 
Plasmid Characteristics Source 
pGL4.10 Basic promoterless Firefly luciferase reporter gene 
plasmid, for insertion of promoter fragments 
Promega 
pGL4.74 Renilla luciferase gene under HSV-TK promoter Promega 
pGL4.13 Firefly luciferase gene under SV40 promoter Promega 
pMICB-470 MICB promoter region 470 bp in pGL4.10 generated within this study 
pMICB-470-
HSE*mut 
MICB promoter region 470 bp in pGL4.10, 
promoter mutated in HSE  
synthesized by MWG 
pMICB-470-
NRF*mut 
MICB promoter region 470 bp in pGL4.10, 
promoter mutated in predicted NRF1 binding site  
generated within this study 
pMICB 225 MICB promoter region 225 bp in pGL4.10 generated within this study 
pMICB 115 MICB promoter region 115 bp in pGL4.10 generated within this study 
pMICA 455 MICA promoter region 455 bp in pGL4.10 generated within this study 
pHβAPr-
hHSF1ΔRD 
expression vector for a constitutive active form of 
human HSF1 (hHSF1ΔRD)  driven by β-actin 
promoter 
kindly provided by A. Nakai 
(Nakai et al., 2000; Gunnung 
et al., 1987) 
pHβAPr-1-neo expression vector containing β-actin promoter generated within this study by 
excision of hHSF1ΔRD 
pLNCX2-
hHSF1ΔRD 
expression vector for a constitutive active form of 
human HSF1 (hHSF1ΔRD) driven by CMV 
promoter 
kindly provided by W. Widlak  
pLNCX2 expression vector containing CMV promoter generated within this study by 
excision of hHSF1ΔRD 
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Primers, siRNA  Sequence: 5’ → 3’ 
Real-time RT-PCR primers and probes 
MICA Fw CGATATCTAAAATCCGGCGTAGTC 
 Rev TGCGGGTGACATTCACCAT 
 Probe FAM-AGGAGAACAGTGCCC-MGB 
MICB Fw TGCAGAAACTACAGCGATATCTGAA 
 Rev TGCATGTCACGGTGATGTTG 
 Probe FAM-CCATGGTGAATGTCAC-MGB 
   
Primer for MIC promoter regions (Cloning) 
MICA-455 bp Fw ATAAGACTCGAGACTCTACAGCCAGG 
 Rev ATAAGACCATGGTGCCAGCCAGAAGCAGGAAGACC 
MICB-470 bp Fw ATAAGAAAGCTTACGCGTTGTCTGTCCCGGAAG 
 Rev ATAAGACCATGGAGGCGACGGCCAGAAACAGCAG 
MICB-225 bp Fw ATAAGAAAGCTTTCCCGCCTTCTAAATTTCCCC 
 Rev ATAAGACCATGGAGGCGACGGCCAGAAACAGCAG 
MICB-115 bp Fw ATAAGAAAGCTTACTGGATAAGCGGTCGCTGAGC 
 Rev ATAAGACCATGGAGGCGACGGCCAGAAACAGCAG 
   
Site-directed mutagenesis  (nucleotide substitutions shown in bold, wild type in parentheses) 
MICB-470 NRF1*mut Fw ATTTTGGCTGCGCTCGTA(CG)CACGCTCCCCCTTTTC 
 Rev GAAAAGGGGGAGCGTGTA(CG)CGAGCGCAGCCAAAAT 
 
Chromatin immunoprecipitation 
MICB-ChIP1 Fw TCCCGCCTTCTAAATTTCCCC 
 Rev TGAATGAAACCGGTGAGAAGAC 
MICB-ChIP2 Fw ACTGGATAAGCGGTCGCTGAGC 
 Rev AGGCGACGGCCAGAAACAGCAG 
   
siRNA duplexes  5’ → 3’  (Source: Page et al., 2006)  
Human HSF1  GUCGUCAACCCGCUCAUUAUU 
 sense GUCGUCAACCCGCUCAUUA 
 antisense GAAUGAGCUUGUUGACGAC 
Luciferase (contr)  CGUACGCGGAAUACUUCGCDTDT 
 sense CGUACGCGGAAUACUUCGC 
 antisense UCGAAGUAUUCCGCGUACG 
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Antibodies  
Non-coupled antibodies 
Antibody (clone) Specificity 
Applica
tion 
Conc /ml 
Working 
conc 
Source 
MICA (AMO1) Monoclonal mouse anti-human, 
IgG1 
FACS 1 mg  
0.2 µg 
/sample 
BAMOMAB 
MICB (BMO2) Monoclonal mouse anti-human, 
IgG2a 
FACS 1 mg  
0.2 µg 
/sample 
BAMOMAB 
ULBP1 (170818) Monoclonal mouse anti-human, 
IgG2a 
FACS 500 µg  
0.1 µg 
/sample 
R&D 
systems 
ULBP2 (BUMO1) Monoclonal mouse anti-human, 
IgG1 
FACS 1 mg  
0.2 µg 
/sample 
BAMOMAB 
ULBP3 (166510) Monoclonal mouse anti-human, 
IgG2a 
FACS 500 µg 
0.1 µg 
/sample 
R&D 
systems 
HLA class I (-A, -B; -
C) (W6/32) 
Monoclonal mouse anti-human, 
IgG2a 
FACS hybridoma 
5 µl 
/sample 
ATCC 
MICA/B (BAMO1) Monoclonal mouse anti-human, 
IgG1 
WB 1 mg  1 µg /ml BAMOMAB 
MICB Polyclonal gat anti-human 
WB 0.2 mg 1 µg /ml 
R&D 
systems 
HSF1 Polyclonal rabbit anti-mouse WB 
CHIP 
1 mg 
1 µg/ml 
10 µg  
Stressgen 
Ubiquitin (FK2) Monoclonal mouse anti-human, 
IgG1 
WB 1 mg 1 µg/ml Stressgen 
H2A Polyclonal rabbit anti-human WB 
CHIP 
500 µg 
1 µg/ml 
5 µg 
Active Motif 
uH2A (E6C5) Monoclonal mouse anti-human 
IgM 
WB 
CHIP 
— 1:1000 Millipore 
GAPDH (14C10) Polyclonal rabbit anti-human 
WB — 1:5000 
Cell 
Signaling 
IgG Rabbit anti-mouse IgM, µ chain CHIP 2.4 mg 5 µg Dianova 
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Coupled secondary antibodies     
Antibody (clone) Specificity 
Applica 
tion 
Conc /ml 
Working 
conc 
Source 
R-Phycerythrin (PE) Goat anti-mouse F(ab’)2 
fragment, IgG 
FACS 0.5 mg 
0.25 µg 
/sample 
Dianova 
IgG, Horseradish 
peroxidase linked 
(HRP) 
ECL, polyclonal donkey anti-
rabbit WB — 1:10000 
GE 
Health 
care 
IgG, HRP ECL, polyclonal rabbit anti-
goat 
WB — 1:2000 
DakoCyt
omation 
IgG, HRP ECL, goat anti-mouse IgG2a WB — 1:5000 Biozol 
IgG, HRP ECL, polyclonal goat anti-
mouse IgM, µ Chain specific 
WB 0.8 mg 1:1000 Dianova 
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3.2 Methods 
3.2.1 Cell culture and treatment 
Human melanoma cell lines UKRV-Mel-02, MA-Mel-47, MA-Mel-86b, MA-Mel-103, 
MA-Mel-107, established in our laboratory from tumor metastasis, human cervical carcinoma 
HeLa cells and human colon carcinoma HCT116 cell line were cultivated in RPMI 
1640/2mmol/L glutamine supplemented with 10 % FCS, 100 U/ml penicillin and 100 µg/ml 
streptomycin at 37°C in a humidified atmosphere with 5 % CO2. Cells were seeded at 50 – 60 
% confluence 24 hrs before treatment. 
MG132, Cycloheximide, Chloroquine, Brefeldin A and Actinomycin D were 
resuspended as recommended by the manufacturer and used at the indicated concentrations. 
Control cells were treated with solvent. 
3.2.2 Flow cytometry 
To determine the surface expression of NKG2DL and classical human MHC class I 
molecules (HLA-A, -B, -C), tumor cells were harvested, washed with PBS, counted and 
resuspended in in FASC buffer at concentration 1 x 106 cells/ml. Of each sample 2 x 105 cells 
(200 µl) were used for the staining, transferred in 96 well plates. Primary antibodies were 
added and samples were incubated on ice for 30 min, than centrifuged at 1500 rpm for 5 min 
and washed twice with 200 µl FACS buffer. Then a secondary antibody conjugated with 
phycoerythrin (PE) was added. The suspension was incubated in the dark on ice for 30 min, 
than centrifuged at 1500 rpm for 5 min and washed twice with 200 µl FACS buffer. Finally 
cells were fixed in 4 % PFA and stored at 4°C or immediately measured using Gallios 
Cytometer and analysed by FlowJo 7.2.2 software. 
3.2.3 Annexin V / PI staining 
To determine the basal and induced apoptosis level, melanoma cell lines were incubated 
with MG132 or with solvent contol DMSO for 8 hrs, then harvested and washed twice with 
ice-cold PBS followed by the centrifugation steps at 1200 rpm for 7 min at 4°C. Washed cells 
were resuspended in 1 x Binding buffer at concentrations of 1 x 106 cells/ml. Of each sample 
1 x 105 cells (100 µl) were used for the staining and transferred in a 5 ml culture tube. 5 µl of 
APC Annexin V (for one or two color analysis) and 1 µl of PI (for two color analysis only) 
were added to the probe, gently vortexed and incubated in the dark for 15 min at RT. After 
incubation 400 µl of 1 x Binding buffer was added to each tube. The measurement was 
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perforemed within 1 hr after staining using Gallios Cytometer and analyzed by FlowJo 7.2.2 
software; the samples during measurement were kept on ice.  
3.2.4 Western blot 
To prepare cell lysates, cells were trypsinized, washed with PBS followed by a 
centrifugation step at 1200 rpm for 7 min. Cells were resuspended in 1 ml PBS and the cell 
number was determined and cells were transferred into 1.5 ml microcentrifuge tubes, 
centrifuged at 2000 rpm for 10 min at 4°C. The supernatant was discarded; the undisturbed 
cell pellet was immediately placed into liquid nitrogen. Cell pellets were either stored at –
80°C or immediately used for protein isolation. Cell pellets were lysed by RIPA buffer 
supplemented with complete protease inhibitor (Roche) in the ratio 100 µl to 4 µl (10 x), 
respectively. 50 µl of completed RIPA buffer was used for lysis of 106 cells. After 15 min 
incubation on ice samples were clarified by centrifugation at 13000 rpm for 15 min at 4°C, 
supernatants containing proteins were collected and either stored at –80°C or used 
immediately for SDS-PAGE electrophoresis. Protein concentrations of the lysates were 
determined with the Bradford method in 96 well plates in triplicates according to 
manufacturer protocol for micro volumes (Sigma). BSA (2 mg/ml; BioRad) was used for a 
standard curve, to determine the concentration in the lysats. Equal amounts of protein (µg) 
were supplemented with 5 µl of sample buffer and adjusted with electrophoresis buffer to 20 
µl. The mixtures were heated at 99°C for 5 min, chilled on ice and loaded onto a SDS 
polyacrylamide gel. After separation proteins were transferred onto a nitrocellulose 
membrane. The membranes were blocked for 1 hour with 5 % non fat dry milk in TBS, 
washed with TBS and incubated with the primary antibodies anti-MICB, -MICA/B, -HSF1, -
Ub, -H2A, uH2A in 1 % TBS-milk and anti-GAPDH in 5 % TBS-bovine serum albumin 
overnight at 4°C, followed by three washing steps in TBS. Membranes were then incubated 
for 1 hr at RT with the horseradish peroxidase (HPR)-coupled secondary antibodies dissolved 
in 1 % TBS-milk, followed by three washing steps in TBS and a last washing with PBS (1 x). 
Antibody binding to membranes was visualized using ECL developing solution incubated 
with the membranes for a maximum of 2 min in the dark.  
3.2.5 Histone extraction 
Cells were trypsinized and washed twice with ice-cold PBS followed by centrifugation 
steps at 1200 rpm for 7 min. The cell pellet was resuspended in Triton Extraction Buffer 
(TEB: PBS containing 0.5 % Triton X 100 (v/v), 2 mM phenylmethylsulfonyl fluoride 
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(PMSF), 0.02 % (w/v) NaN3) at a density of 107 cells/ml and incubated (10 min) on ice with 
gentle stirring. The lysate was centrifuged at 6500 x g for 10 min at 4°C to spin down the 
nuclei. The nuclei pellet was washed in half of the TEB volume and centrifuged at 6500 x g 
for 10 min at 4°C. The pellet was resuspended in 0.2 N HCl at a density of 4x107 nuclei/ml 
and left overnight at 4°C for acid extraction. The extracts were then centrifuged at 6500 x g 
for 10 min at 4°C to pellet the debris. The supernatant was collected and the protein content 
was determined, performing the Bradford assay. The histone extracts were used for Western 
blot and resolved by SDS-PAGE as described before, or stored at -80°C. 
3.2.6 Quantitative RT-PCR 
For RT-RCR, total RNA (free of genomic DNA) was isolated from tumor cells using the 
RNeasy Mini Plus Kit according to the manufacturer protocol. To ensure that genomic DNA 
is not present in the samples an additional step of purification was performed as follows: 80µl 
of DNase I mix (10 µl DNase I Stock solution and 70 µl RDD buffer, supplied) (DNase I, 
RNase-free Set; Qiagen) was added to each sample after the first washing step of the column 
with RW1 buffer (RNeasy Mini Plus Kit, Qiagen) and left to penetrate for 15 min at RT. Next 
proceed to the manufacturer protocol (RNeasy Mini Plus Kit; Qiagen). The concentration of 
total RNA, was measured with Infinite M200 (Tecan). The concentration of a sample 
containing RNA may be calculated following Equation: 40 x OD(260 nm) of the sample = 
concentration of RNA (µg/ml). 1 µg RNA was used for reverse transcription. The reverse 
transcription reaction was performed using high-capacity cDNA reverse transcription kit 
(Applied Biosystems) with reverse transcription random primers. DNA was quantified with 
Infinite M200. The concentration of a sample containing DNA may be calculated following 
Equation: 50 x OD(260 nm) of the sample = concentration of DNA (µg/ml). 
cDNA was amplified with specific primers and probes for MICA and MICB, or using 
predesigned TaqMan gene expression assay kits for HSP70 and GAPDH (endogenous 
control) (Applied Biosystems). For real-time PCR reaction 2 x TaqMan Universal PCR 
Master Mix (no AmpErase UNG) was used. The reaction mixtures were composed as follows: 
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for MICA and MICB for HSP70 and GAPDH 
5 µl (2x) TaqMan master mix 5 µl (2x) TaqMan master mix 
0.3 µl forward primer (1:10; 300 nM) 0.5 µl of primer and probe mix 
0.3 µl reverse primer (1:10; 300 nM)  50 ng cDNA 
1 µl probe (1:100; 100 nM) adjust to 10 µl with Aqua Braun 
50 ng cDNA 
adjust to 10 µl with Aqua Braun  
 
TaqMan PCR amplification was performed using an Applied Biosystems sequencer 
detection system. The cycling conditions were 10 min at 95°C followed by 35 cycles: 20 sec 
at 95°C, 90 sec at 60°C. The final extension was performed at 72°C 10 min. Reactions were 
performed in triplicates. Changes in MICA, MICB and HSP70 expression levels, normalized 
to GAPDH mRNA levels, were calculated by the 2–∆∆CT method (Livak, Schmittgen, 2001). 
3.2.7 Amplification of promoter fragments, cloning and site-directed mutagenesis 
UKRV-Mel-02 cells were trypsinized, washed with PBS followed by centrifugation 
steps at 1200 rpm for 7 min. Washed cells were resuspended in 1 ml PBS and centrifuged at 
2000 rpm (10 min, 4°C). The supernatant was discarded; the undisturbed cell pellet was used 
for the isolation of genomic DNA by the QiaAmpDNA Blood Mini Kit (Qiagen). MICA and 
MICB promoter regions were amplified from genomic DNA with PCR using the Expand 
High Fidelity polymerase (Roche) and specific primers following the manufacturer protocol.  
The thermocycling program was as follows: 94°C – 2 min; 94°C – 15 sec; 69°C – 30 
sec; 72°C – 45 sec, 39 cycles from step 2; 72°C – 10 min; 4°C. PCR products were purified 
with the QIAquick PCR purification kit (Qiagen) according to the manufacturer protocol. 
For cloning of the PCR products into pGL4.10 the following reaction mixtures 
generated: 
 
MICB promoter constructs   pGL4.10 restriction (1 µg/µl) 
purified PCR product 12 µl or 30 µl  pGL4.10 1 µg 
Nco I (10 u/µl) 2 µl 5 µl Nco I (10 u/µl) 2 µl 
Hind III (10 u/µl) 2 µl 5 µl Hind III (10 u/µl) 2 µl 
2 x (10 x Yellow Tango 
buffer) 
 
4 µl 10 µl 
 
2 x (10 x Yellow Tango 
buffer) 
H2O 
4 µl 
 
add to 20 µl 
 V = 20 µl V = 50 µl  V = 20 µl 
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The DNA was incubated with restriction enzymes at 37°C for 4 hrs, enzymes were 
subsequently inactivated at 80°C for 20 min. The products of the restriction reaction were 
purified with the QIAquick nucleotide removal kit following the manufacturer instructions. 
DNA concentration was measured. For ligation, PCR product and linearized vector were 
mixed in the ratio determined by the following equation: Amount of insert [ng] = 5 x amount 
of vector [ng] x (size of insert [bp] / size of vector [bp]). Ligation was performed at RT 
overnight followed by an inactivation step at 65°C – 10 min.  
 
Vector  calculated 
Insert  amount 
10 x Ligase buffer 2 µl 
T4 Ligase 1.5 µl 
H2O add. to 20 µl 
 
3.2.8 Transformation and DNA isolation  
One Shot TOP10 chemically competent Escherichia Coli (Invitrogen) were transformed 
with the ligation product as follows: 50 µl of TOP10 cells were mixed with 20 µl ligation 
product and incubated 30 min on ice; the suspension was then incubated for 45 sec in a water 
bath at 42°C for heat shock and chilled on ice for 3 min. SOC medium (300 µl) was added to 
the bacteria and the suspension was incubated for 1 hr at 37 °C, 250 rpm. Then 100-150 µl of 
the E. coli suspension was spread onto the agar dishes containing ampicillin (100 µg/ml) and 
incubated overnight at 37 °C.  
For DNA isolation bacterial colonies were picked, placed into a glass tube with 5 ml 
sterile LB medium supplemented with ampicillin (100 µg/ml) and incubated overnight at 
37°C in a shaker (200 rpm). Of the bacterial suspension 4 ml were collected to isolate plasmid 
DNA using the GeneJet Plasmid Miniprep Kit (Fermentas), 1 ml was left at 4°C to use for 
maxi-prep. Concentration of the isolated DNA was measured and restriction of 0.5 µg DNA 
was performed to confirm the presence of the insert in the plasmid.  
Following constructs were generated: pMICA-455 bp, pMICB-470 bp, pMICB-225 bp, 
pMICB-115 bp. MICB promoter element mutation in HSE was synthesized by MWG Operon 
Eurofins. The mutation in the NRF1 binding site was made by mutagenic megaprimer NRF1* 
PCR (34) using the pMICB-470 construct and QuikChange-II site-directed mutagenesis 
methodology (Stratagene). All DNA fragments in pGL4.10 were verified by sequencing. 
The correct constructs confirmed by sequencing were amplified in 100 ml of LB 
medium supplemented with ampicillin (100 µg/ml) (for high copy plasmids) and incubated 
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overnight at 37°C, 200 rpm. Plasmid DNA was isolated with Plasmid Maxiprep Kit (Qiagen) 
according to the manufacturer protocol.  
3.2.9 Transfection and luciferase assay 
Melanoma cells were seeded in 6-well plates at 1.5 x 105 cells/well. After 24 hrs cells 
were transiently transfected with luciferase reporter gene expression plasmid DNA (1 
µg/well) together with the internal control plasmid pGL4.74, encoding Renilla luciferase (200 
ng/well), used for normalisation. As negative control the luciferase promoterless pGL4.10 
vector was used (mock), as positive control pGL4.13 containing the Firefly luciferase gene 
driven by SV40 promoter was used. For DNA transfection the Fugene transfection reagent 
(Roche) was used. Transfected melanoma cells were incubated for 24 hrs, then 10 µM 
MG132 or solvent (DMSO) were added. Cells were incubated for 8 hrs, then washed twice 
with PBS. 500 µl (1 x) Reporter lysis buffer (Promega) was added to each well, plates were 
immediately placed at -80°C and incubated there for 10 min. Frozen plates were placed at 
37°C for thawing, then lysates were harvested, transferred into 1.5 ml microcentrifuge tubes 
and then placed into liquid nitrogen. The lysates were either stored at -80°C or immediately 
used for measurement of luciferase activity. For the luciferease assay the lysates were thawed 
at 37°C in a water bath. Of the lysate 75 µl were used to measure Firefly and Renilla 
luciferase activities in triplicates using the DuaL-Glo Luciferase Assay System (Promega) in 
96-well white flat bottom luminometer plates (Costar) using the Infinite 2000 system (Tecan) 
and the IControl software. Promoter construct activities were determined by normalizing 
Firefly luciferase activities to Renilla luciferase activities. 
In some assays, an HSF1 expression plasmid and a corresponding control plasmid were 
transfected in addition. 
Statistic analysis was done by GraphPad Prism program using standard paired t-test. 
3.2.10 Transfection of siRNA 
For HSF1 knock-down, cells were seeded in 6-well plates at 1.5 x 105 cells/well. After 
24 hrs cells were transfected with HSF1-specific siRNA or luciferase-specific siRNA 
(negative control) at 2 µg/well using the X-treme Gene Transfection Reagent (Roche). siRNA 
transfection reagent and si RNA were mixed at a ratio 1:5. The cells were incubated for 72 hrs 
followed by treatment with proteasome inhibitor. 
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3.2.11 Chromatin immunoprecipitation (ChIP) assay  
Melanoma cells, either treated with the proteasome inhibitor MG132 (10 µg/ml) for 4 
hrs or left untreated, were harvested and processed for ChIP using the ChIP-IT Enzymatic kit 
following the protocol of the manufacturer (Active Motif, USA). Antibodies for 
immunoprecipitation were used as recommended by the manufacturer: mouse IgG control 2 
µg/ChIP reaction and anti-HSF1, anti-uH2A 5 µg/ChIP reaction. For mouse anti-human 
uH2A (IgM) mAb the preincubation of 25 µl G-protein magnetic beads with rabbit anti-
mouse IgM (4 µg) Ab adjusted with water up to 100 µl was nessesary for 1 hr at 4°C, by 
shaking. Then beads were washed with 100 µl of ChIP buffer 1 and proceed to the 
immunoprecipitation with uH2A mAb according to the manufacturer protocol. As an 
additional control rabbit anti-mouse IgM (4 µg) Ab were immunoprecipitated without adding 
uH2A to confirm the specificity of the bands in the immunoprecipitates with uH2A. 
Immunocomplexes were collected with G-protein magnetic beads and sequentially washed. 
Chromatin was eluted, digested with proteinase K and the cross-linking was reversed, as 
detailed in the kit protocol. Purified DNA was further used for PCR with Thermoprime Taq 
DNA polymerase. Fractions of chromatin were processed similar to immunoprecipitated 
chromatin for input DNA controls. The forward and reverse primers for PCR amplification 
are listed above. Thermocycling procedure was as follows: 95°C – 2 min; 35 cycles: 95°C – 
25 sec; 59°C (for ChIP1) or 66°C (for ChIP2) – 35 sec; 72°C – 65 sec. The final extension 
was performed at 72°C – 5 min. 
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4 Results 
Ligands of the NKG2D receptor, the MIC and ULBP molecules, sensitize melanoma 
cells for recognition by NK cells (Schwinn*, Vokhminova* et al., 2009; *shared first 
authorship), suggesting that therapeutic upregulation of these molecules should be supportive 
in terms of an effective anti-tumor immune response. Small molecule inhibitors that induce 
stress in tumor cells like inhibitors of the proteasome have been demonstrated to up-regulate 
NKG2DL expression on myeloma and hepatocellular carcinoma (Salih et al., 2003; Jinushi1 et 
al., 2003), but the molecular mechanisms behind remain unknown. The aim of this study was 
to determine the impact of proteasome inhibition on NKG2DL expression in melanoma cells 
and to elucidate the underlying molecular mechanisms.  
4.1 Proteasome inhibition up-regulates surface expression of NKG2D ligands  
4.1.1  Short-term proteotoxic stress exclusively induces MICB surface expression 
To test the influence of proteasome inhibition on NKG2DL expression, the two 
melanoma cell lines UKRV-Mel-02 and MA-Mel-86b, already known to express NKG2DL 
(Schwinn, Vokhminova et al., 2009), as well as three additional metastatic cell lines MA-Mel-
47, MA-Mel-103 and MA-Mel-107 were selected for this study. Furthermore the cervix 
carcinoma cell line HeLa and the colon carcinoma cell line HCT116 were included in some 
experiments in order to compare melanoma cells to tumor cells from other entities. Analysis 
of the indicated cell lines for the surface expression of individual NKG2DL by flow 
cytometry revealed different patterns (Fig. 1). The ligand most prominently expressed on all 
melanoma cells was MICA, while MICB was present only on 4 out of the 5 melanoma cell 
lines and its basal expression was quite low. In contrast to melanoma, the cell lines HeLa and 
HCT116 showed much stronger MICA and MICB surface expression. Of the ULBP family 
the ligand ULBP2 was most prominently expressed, with modest expression on MA-Mel-47 
and HeLa to relatively strong levels on MA-Mel-86b, Ma-Mel-103 and HCT116. All cell 
lines were negative for ULBP1 and ULBP3 (data not shown), with the exception of MA-Mel-
47, which expressed low amounts of ULBP1 on the surface (data not shown). To analyse if 
induction of proteoxic stress elicited by proteasome inhibition influences NKG2DL 
expression, the tumor cell lines were treated with proteasome inhibitor MG132 and analyzed 
for NKG2DL surface expression (Fig. 1). 
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Figure 1. Surface expression of NKG2DL on tumor cells 
The indicated human tumor cell lines were treated either with MG132 (10 µM) (solid black line 
histograms) or with DMSO (solvent, gray shaded histograms) for 8 hrs, then washed and incubated 
with unconjugated mouse anti-human MICA, MICB, ULBP2 or HLA class I specific mAb, followed 
by staining with PE-conjugated goat F(ab’)2 anti-mouse IgG. Cells were then analyzed by flow 
cytometry. Representative data from one of at least two independent experiments are presented. 
Results 42 
Already after 8 hrs, 4 out of 5 melanoma cell lines showed an up-regulation of MICB 
expression, though to different extent. Similarly, HeLa cells upregulated MICB, while no 
NKG2DL modulation could be observed for HCT116. In contrast to MICB, expression of 
MICA and ULBP2 was not up-regulated, noteworthy, even the level of classical HLA class I 
molecules remained constant. The induction of MICB was not caused by apoptosis as shown 
by a control Annexin V / PI staining (see Appendix, Fig. A1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Up-regulation of NKG2DL surface expression on melanoma cells upon proteasome 
inhibition 
Human melanoma cell lines UKRV-Mel-02 and MA-Mel-47 were stained with unconjugated 
mouse anti-MICA, MICB, ULBP1, ULBP2, ULBP3 mAb followed by PE-conjugated goat F (ab’)2 
anti-mouse IgG and analyzed by flow cytometry for NKG2DL surface expression. Gray lines – 
background staining with secondary PE–conjugated antibody only. 
A. UKRV-Mel-02 or MA-Mel-47 cells were incubated with MG132 (10 µM) (black lines) or with 
DMSO (solvent, gray shaded histograms) for 8 hrs. 
B. UKRV-Mel-02 or MA-Mel-47 cells were treated either with MG132 (10 µM) (black lines) or 
with DMSO (solvent, gray shaded histograms) for 8 hrs then washed and incubated in the absence of 
MG132 for additional 24 hrs. Data are representative from one of four independent experiments.  
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4.1.2 Prolonged proteotoxic stress induces expression of multiple NKG2D ligands on 
melanoma cell lines 
Among the melanoma cell lines UKRV-Mel-02 and MA-Mel-47 were most sensitive to 
proteasome inhibitor treatment in terms of MICB up-regulation. These cells were chosen for 
further experiments to study the underlying molecular mechanisms. Since MG132 is a potent 
but reversible inhibitor of the proteasome, it was determined, whether increased MICB 
expression on melanoma cells persisted in the absence of MG132. Therefore, UKVR-Mel-02 
and Ma-Mel-47 cells were treated with MG132 for 8 hrs and either harvested for direct 
analysis (Fig. 2A) or washed and incubated for additional 24 hrs in medium without inhibitor 
and then studied for NKG2DL surface expression by flow cytometry (Fig. 2B). Again 
treatment of melanoma cells with MG132 for 8 hrs and subsequent analysis revealed a clear 
induction of MICB expression on both melanoma cell lines. In case cells were cultured in 
medium alone for additional 24 hrs after proteasome inhibition, elevated levels of MICB were 
still detectable. Interestingly, under these conditions melanoma cells showed increased 
surface expression also of MICA and ULBP2, suggesting that the delayed induction was a 
secondary event. MA-Mel-47 and UKRV-Mel-02 cells showed similar pattern of NKG2DL 
regulation regarding MICA, MICB, ULBP2-3, only for Ma-Mel-47 an increased expression 
of ULBP1 was observed in addition. Taken together, MG132 induces NKG2DL expression 
on melanoma cells and this study focused on the analysis of the early response of MICB, in 
comparison to MICA. 
4.1.3 Up-regulation of MICB protein under MG132 treatment is time-dependent 
As demonstrated above, melanoma cells rapidly increased the expression of MICB upon 
proteasome inhibition. To examine the kinetic of this response melanoma cells were treated 
with MG132 for 2, 4, 6 and 8 hrs and analyzed for the surface expression of MICA and MICB 
(Fig. 3A). While MICA levels remained constant, MICB surface expression increased already 
after the 6 hrs of treatment.  
The increase of MICB surface expression could just be due to an enhanced transport of 
intracellularly stored protein to the cell surface not associated with an increase in the amount 
of total MICB protein. To analyse this whole cell lysates from melanoma cells treated with 
MG132 were prepared and analyzed for total MICB protein levels by Western blot (Fig. 3B). 
A slight but clearly detectable enrichment of total MICB protein was observed already after 2 
hrs of proteasome blockade while a strong increase was detectable after 6 hrs, suggesting that 
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the enhanced MICB surface expression was due to an increase in total specific protein. 
Visualizing of MICB revealed different bands with molecular weights of lower than 40 kD 
and around 55 kD. The diffuse bands around 55 kD represent differently glycosylated forms 
of MICB, while the lowest band about 40 kD represents non-glycosylated MIC (Eleme et al., 
2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. MG132 rapidly up-regulates MICB expression in melanoma cells 
Human melanoma cell lines UKRV-Mel-02 and MA-Mel-47 were treated with MG132 (10µM) 
for 2, 4, 6 or 8 hrs and analyzed for MICA and MICB surface expression and for the total level of 
MICB protein. Data are representative of three independent experiments for UKRV-Mel-02 and of 
two experiments for MA-Mel-47. 
A. UKRV-Mel-02 (top) and MA-Mel-47 cells (bottom) were treated with MG132 (black lines) or 
with DMSO (gray shaded histograms) as the solvent control for 8 hrs and subsequently stained with 
unconjugated mouse anti-MICA or anti-MICB mAb followed by PE-conjugated goat F (ab’)2 anti-
mouse IgG. Cells were analyzed by flow cytometry for MICA and MICB surface expression. Gray 
lines, background staining with the secondary PE–conjugated antibody only. Logarithmic scale of 
histograms: 100-103 for UKRV-Mel-02, 101-105 for MA-Mel-47. 
B. UKRV-Mel-02 (top) or MA-Mel-47 cells (bottom), after the treatment with MG132 for the 
indicated time periods, were harvested and whole cell lysates were analyzed by Western blot for 
MICB total protein expression. The protein samples were separated by SDS-PAGE and probed with a 
polycloncal anti-MICB antibody (R&D). The arrows show the unglycosylated MICB (about 38 kD) 
and the glycosylated form of MICB protein (about 55 kD). C, indicates control cells treated with 
DMSO for 8 hrs. GAPDH was used as the loading control.  
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4.2 Upregulation of MICB upon proteasome inhibition is dependent on 
translation 
Inhibition of the proteasome blocks protein degradation. To determine if stabilization of 
the MICB protein is responsible for the up-regulation of its surface presentation on 
melanoma, cells were treated with a combination of MG132 and Cycloheximide (CHX). The 
latter is known as an inhibitor of translation in eukaryotic cells. In cells treated with MG132 a 
strong induction of MICB was observed as shown by Western blot analysis. This upregulation 
was abrogated in the presence of CHX, indicating that translation is essentially required for 
the induction of MICB expression on melanoma cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Induction of MICB by MG132 is abrogated in the presence of cycloheximide 
UKRV-Mel-02 (top) and MA-Mel-47 cells (bottom) were treated either with MG132 (10 µM), or 
with Cycloheximide (100 µg/ml), or with both simultaneously for 2, 4, 6 and 8 hrs. Control cells were 
left untreated or DMSO as solvent control was added. Whole cell lysates were analyzed by Western 
blot for MICB total protein. Anti-MICA/B mAb recognized both MICA and MICB proteins in the 
tested lysates. GAPDH was used as a loading control. The blots are representative of three 
independent experiments. 
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Cells treated with MG132 and CHX showed slightly higher levels of MICB protein in 
comparison to cells treated with CHX alone (Fig. 4). This suggests that upon MG132 
treatment there is a certain increase in MICB stability that, however, does not play the major 
role in MG132-induced MICB upregulation. 
4.3 MICB up-regulation is caused by proteasome inhibition but not by 
blockade of lysosomal degradation  
Proteasome inhibitor MG132 can effectively block proteosomal degradation of 
polyubiquitinated proteins. Moreover, MG132 was also described to be able to block the 
lysosomal degradation of proteins (Nice et al., 2009). To determine the role of lysosomal 
degradation in MICB induction, melanoma cell lines were treated with chloroquine, which 
inhibits lysosomal degradation without affecting proteasomal degradation. Unlike MG132, 
chloroquine did not change surface expression of MICB within 8 hrs of treatment (Fig. 5). 
Thus, the inhibition of lysosomal degradation did not contribute to the rapid MICB induction 
under MG132 treatment.  
 
 
 
 
 
 
 
 
 
 
Figure 5. Inhibiton of lysosomal proteases does not induce MICB expression 
UKRV-Mel-02 and MA-Mel-47 cells were treated either with Chloroquine (50 µM, top), or with 
MG132 (10 µM, bottom) or with DMSO (solvent control) for 8 hrs and then analyzed for MICA, 
MICB and HLA class I surface expression by flow cytometry. Solid black line historgrams represent 
inhibitor treated cells, gray shaded histograms indicate control cells treated with DMSO (solvent). 
Gray line histograms – background staining with the secondary PE–conjugated antibody only. 
Representative data from one of two independent experiments are shown. 
4.4 Transcriptional up-regulation of MICB expression under proteasome 
inhibition 
To elucidate the underlying molecular mechanism of MICB upregulation, the influence 
of proteasome inhibition on MICB specific mRNA levels was determined. Upon MG132 
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treatment MICB mRNA levels in UKRV-Mel-02 and Ma-Mel-47 cells were strongly induced 
(Fig. 6), whereas MICA specific mRNA levels were hardly affected. Up-regulation of MICB 
mRNA was time-dependent. Compared to untreated cells the specific mRNA levels were 
around three fold increased in UKRV-Mel-02 and more that six fold in MA-Mel-47 cells after 
8 hrs of proteasome inhibition.  
To determine if the increase in MICB mRNA levels was due to an enhanced mRNA 
stabilization or an activation of transcription, melanoma cells were treated with MG132 or 
with MG132 in combination with Actinomycin D, which is known as a potent inhibitor of 
transcription. Control cells were treated either with DMSO as solvent control or with 
Actinomycin D alone. As shown in Figure 6, the addition of Actinomycin D completely 
blocked the induction of MICB mRNA by proteosomal stress, which suggests that MG132 
indeed potentiates MICB transcription. 
 
Figure 6. Proteasome inhibition transcriptionally regulates MICB expression in melanoma cells 
Quantitative real time PCR analysis of MICA (left) and MICB (right) mRNA expression in 
melanoma cells UKRV-Mel-02 (top row) and MA-Mel-47 (bottom row) after treatment either with 
MG132 (10µM) alone, with Actinomycin D (1µg/ml) alone or with a combination of both drugs for 
the indicated period of time. Control cells were treated with DMSO for 8 hrs and set to one. MIC 
mRNA levels were normalized to endogenous GAPDH levels. PCR reactions were performed in 
triplicates, error bars indicate standard deviation (SD). One representative experiment of two 
experiments for each cell line is shown. 
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Again the influence of chloroquine on MICB mRNA levels was tested. Corresponding 
to the surface expression, no changes in MICA and MICB mRNA expression level were 
detected in melanoma cells after chloroquine treatment for 8 hrs, while cells treated with 
MG132 strongly increased MICB mRNA levels (Fig. 7).  
 
	  
Figure 7. Proteasome blockade but not lysosome inhibition stimulates MICB mRNA up-
regulation 
UKRV-Mel-02 and MA-Mel-47 cells were treated either with Chloroquine (50 µM), or with 
MG132 (10 µM) for 8 hrs and analyzed by qRT-PCR for MICA and MICB mRNA expression. 
Control cells were treated with DMSO (solvent) for 8 hrs and set to one. MIC mRNA levels were 
normalized to endogenous GAPDH levels. PCR reactions were performed in triplicates, error bars 
indicate SD. 
4.4.1 Activation of the MICB promoter under proteasome blockage  
Recently, promoter regions of the MICA and MICB genes, cloned from colon 
carcinoma cells HCT116, were described (Venkataraman et al., 2007, Rodríguez-Rodero et 
al., 2007), which comprised about 500 bp upstream of the translational start side (nucleotide 
position +1). To determine putative transcription factor binding sites (TFBS) within this 
region, that are involved in the induction of MICB transcription by MG132, the corresponding 
nucleotide sequence was analyzed using the MatInspector (Genomatix) database, which 
predicts potential TFBS based on a weighted matrix approach (Fig. 8A). For both MIC 
molecules heat shock responsive elements (HSE) were predicted at –200 and –185 bp 
upstream of the start codon for MICA and MICB, respectively. The HSE sites were shown to 
be relevant for the up-regulation of MIC expression under heat shock and oxidative stress 
(Venkataraman et al., 2007). Interestingly, the activation of HSF1 in MG132 treated cells has 
been indirectly demonstrated via activation of HSP70 a direct target of HSF1 (Bush et al., 
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1997). Moreover, a putative binding site for Nuclear respiratory factor 1 (NRF1) was 
predicted about 60 bp upstream of the HSE within the MICB promoter, which could play a 
role in the expression regulation of MIC molecules under the oxidative stress. 
To study the MIC promoter activity under proteotoxic stress a number of MICB and one 
control MICA promoter constructs were generated by cloning fragments into the promoterless 
pGL4.10 vector: pMICB–470; pMICB–225; pMICB–115 and pMICA–455, encompassing 
470 bp, 225 bp and 115 bp and 455 bp upstream of the start codon, respectively (Fig. 8B). 
These constructs were tested for their ability to drive the Firefly luciferase reporter gene in 
transiently transfected melanoma cells (Fig. 9). For normalization the pGL4.10 derivatives 
were co-transfected with the pGL4.74 plasmid, containing the Renilla luciferase gene under 
control of the HSV-TK promoter. 
The transfection experiments revealed that the strength of the luciferase signal in cells 
transfected with the pMICB-225 construct was at least two fold lower compared to cells 
transfected with the pMICB-470 plasmid. The pMICB-115 construct did not yeld any 
detectable luciferase signal. To study the effect of proteasome inhibition on MICB promoter 
activity, UKRV-Mel-02 and MA-Mel-47 cells treated with MG132 24 hrs after transfection 
(Fig. 9). The luminescent signal obtained for proteasome-inhibitor treated cells transfected 
with pMICB–470 and pMICB–225 constructs were about three fold stronger for UKRV-Mel-
02 and ten fold and five fold stronger in MA-Mel-47 cells compared to untreated controls. No 
induction in luciferase activity after proteasome inhibition was detected for cells transfected 
with the pMICB–115 plasmid, which does not contain any HSE. Cells transfected with 
pMICA-455 showed three (UKRV-Mel-02) to five fold (MA-Mel-47) higher luciferase 
expression under MG132 treatment. Mock-transfected cells displayed similar luciferase 
activities under all conditions. In contrast activity of the positive control plasmid pGL4.13 
containing the firefly luciferase under control of the SV40 early enhancer/promoter region, 
which provides strong luciferase expression was down-regulated under MG132 treatment. 
The same was true for the Renilla luciferase expression plasmid pGL4.74, used for 
normalization. Therefore, the Renilla luciferase values from DMSO-treated cells were used 
for normalization of Firefly luciferase signals of both DMSO-treated and proteasome inhibitor 
treated cells. 
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Figure 8. MICB and MICA promoter constructs  
A. Sequence of the MICB promoter region. The arrow indicates the start codon, marked by +1. 
Predicted binding sites for transcription factors are given in bold and underlined.  
B. Schematic presentation of the MICB and MICA promoter fragments cloned into the pGL4.10 
vector and used for the studies on MIC promoter activity under proteotoxic stress. HSE – heat shock 
responsive element; NRF1 – nuclear respiratory factor 1 binding site. For analysis of the MICB 
promoter activity five different constructs were generated, containing fragments of the following 
size/characteristics: –470 bp; –470 bp/HSE* with mutated binding site for HSF1; –470 bp/NRF1* 
with mutated predicted NRF1 binding site; –225 bp; –115 bp for MICB and –455 bp for MICA. 
 
Thus, proteotoxic stress significantly stimulates MICB promoter activity and the 
presence of heat shock responsive element located about 200 bp upstream the translation start 
seems to be essential for enhancing MICB transcription.  
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Figure 9. Influence of the proteotoxic stress on MIC promoters in melanoma cells 
Indicated are the Firefly luciferase reporter gene activities driven by MICB and MICA promoter 
fragments of the indicated length. The MICB and MICA promoter constructs were transiently 
transfected in UKRV-Mel-02 and MA-Mel-47 cells. Control cells were transfected either with the 
promoterless pGL4.10-basic vector (mock), the pGL4.13 positive control plasmid or left 
untransfected. For normalization Renilla luciferase expression plasmid pGL4.74 was co-transfected. 
After 24 hrs, 10 µM MG132 or DMSO (solvent control) were added, cells were incubated for 8 hrs, 
then harvested and analyzed for Firefly and Renilla luciferase activities. Assays were done in 
triplicates. Data are means of at least five independent experiments. Error bars indicate SD. 
 
4.4.2 The HSF1 and the potential NRF1 binding sites are relevant for MICB promoter 
activity 
In order to analyze the functional significance of the HSF1 and the predicted NRF1 
binding sites for MICB transcription under proteotoxic stress, pMICB–470 derivatives with 
specific mutations in the corresponding DNA elements were generated yielding pMICB-
470/HSE* and pMICB-470/NRF1*. In transfected melanoma cells the pMICB-470/HSE* 
constructs mediated a slightly decreased luciferease activity compared to pMICB-470. More 
important, under MG132 treatment the induction of luciferase activity for the pMICB-
470/HSE* constructs was almost completely abrogated (Fig. 10), indicating that binding of 
HSF1 to HSE is essential for MICB promoter activation by proteotoxic stress. The cells 
transfected with pMICB-470/NRF1* showed diminished luciferase activity pointing out the 
relevance of this element for MICB expression in melanoma cells. The response of this 
construct to proteasome inhibition was also impaired. 
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Figure 10. Effect of mutations in HSF1 and putative NRF1 binding sites on MICB promoter 
activity 
A. Part of promoter region sequences around the known shock responsive element (HSE) and the 
putative nuclear respiratory factor 1 binding site (NRF1). Conserved nucleotides of the binding sites 
are underlined. The nucleotides in bold were exchanged by site-directed mutagenesis. 
B. pMICB-470, pMICB-470/HSE*, pMICB-470/NRF1* and pMICA-455 were transiently 
transfected in UKRV-Mel-02 and MA-Mel-47 cells. Control cells were transfected either with 
pGL4.10 (mock), or with pGL4.13 (positive control) or left untransfected. 24 hrs after the transfection 
10 µM MG132 or DMSO as the solvent control were added, cells were incubated for 8 hrs, then 
harvested and analyzed for luciferase activity. Assays were done in triplicates. Data are representative 
of at least three independent experiments with pMICB-470/HSE*, only the pMICB-470/NRF1* 
construct was tested in two independent experiments. (*, p = 0.0372). 
Statistic analysis was done by GraphPad Prism program using standard paired t-test. 
 
4.5 Proteotoxic stress mediated MICB induction is controlled by HSF1 
4.5.1 Expression of a constitutive active HSF1 variant stimulates MICB reporter gene 
activity 
Both, the MICA and MICB promoter region contain a HSE sequence about –200 bp 
upstream of the ATG start codon. As described above, the mutation of the HSF1 binding site 
within the MICB promoter interfered with the induction of promoter activity by MG132 
treatment and suggests that, indeed, HSF1 stimulates MICB transcription under proteotoxic 
stress. To further examine the role of HSF1, a constitutively active form of HSF1 was 
expressed in melanoma cells. The constitutively active HSF1 variant is deleted of a regulatory 
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domain that normally suppresses the C-terminal activation domain of HSF1. The active HSF1 
variant was encoded by the two different expression plasmids pHβAPr-hHSF1ΔRD and 
pLNCX2-hHSF1ΔRD. The construct pHβAPr-hHSF1ΔRD mediates expression of HSF1 by 
the human β-actin promoter, while on pLNCX2-hHSF1ΔRD the human cytomegalovirus 
promoter activates HSF1 expression. As controls the empty vectors, deleted of the inserts, 
were used. To analyze the effect of active HSF1 on MICB promoter activity melanoma cells 
were co-transfected with the HSF1 expressing plasmids and the different pMICB and pMICA 
reporter gene constructs (Fig. 11).  
Co-transfection of pMICB–470 and pMICB–225 with pHβAPr-hHSF1ΔRD led to a ten 
fold up-regulation of luciferase reporter gene activity, while co-transfection with the control 
vector pHβAPr-1-neo yielded signals comparable to those obtained for transfection of pMICB 
constructs alone. Similar to pHβAPr-hHSF1ΔRD also the HSF1 expression plasmid 
pLNCX2-hHSF1ΔRD induced reporter gene expression. Co-transfection of the HSF1 
expression plasmids with pMICB–115 or pGL4.10 did not lead to any reporter gene 
expression. Constitutive active HSF1 also induced activity of the MICA promoter on pMICA-
455, similar to pMICB–470.  
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Figure 11. Influence of constitutive active HSF1 on the activity of the MIC promoters 
The different MICB (pMICB–470, pMICB–225, pMICB–115) and MICA (pMICA–455) 
promoter constructs were transiently transfected into UKRV-Mel-02 and MA-Mel-47 cells. Control 
cells were transfected with pGL4.10 (mock, neg. control) or with pGL4.13 (positive control). Where 
indicated, cells were cotransfected with expression plasmids (pHβAPr-hHSF1ΔRD, pLNCX2-
hHSF1ΔRD) for constitutive active HSF1 (HSF1ΔRD), or with empty control plasmids (pHβAPr-1-
neo, pLNCX2). NT – cells transfected with HSF1 plasmids (or control plasmids) without pGL4 
luciferase bearing vectors only. Twenty-four hrs after transfection cells were harvested and analyzed 
for luciferase activity. Assays were done in triplicate. Data are representative of at least three 
independent experiments. Error bars indicate SD. 
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4.5.2 Constitutive active HSF1 does not affect endogenous MICB  
As described above, constitutive active HSF1 could induce reporter gene expression 
driven by the MIC promoters. To examine whether expression of constitutive active HSF1 
also stimulates the endogenous MICA and MICB promoters, melanoma cells were transiently 
transfected with pHβAPr-hHSF1ΔRD or pLNCX2-hHSF1ΔRD and analyzed for the surface 
levels of MICA and MICB molecules (Fig. 12A). There was no difference in the surface 
expression of MICA between cells transfected with the HSF1 expression plasmids, with the 
empty control plasmids or untransfected cells. A slight upregulation of MICB surface 
expression on UKRV-Mel-02 cells was detectable for cells transfected with the plasmids 
pHβAPr-hHSF1ΔRD or pLNCX2-hHSF1ΔRD but was also measurable when cells were 
transfected with the control empty vectors. In MA-Mel-47 cells no effect on the MICB 
surface expression irrespective of the transfected plasmid was observed.  
Also whole cell lysates were prepared from transfected cells and analyzed for the level 
of HSF1 and MICB proteins (Fig. 12B). The plasmid-based expression of constitutive HSF1 
in melanoma cells yielded a band with a molecular weight of about 55 kD. This band was 
detectable in cells transfected with pHβAPr-hHSF1ΔRD or pLNCX2-hHSF1ΔRD. With 
respect to MICB, all plasmids, empty controls as well as HSF1 expression constructs, slightly 
enhanced MICB protein expression as compared to untransfected control, corresponding to 
the observation made for MICB surface expression on these cells. Thus, transfection of 
UKRV-Mel-02 cells with the expression vectors encoding constitutive active HSF1 did not 
induce endogenous MICB levels. This was the case also for MA-Mel-47 cells. 
To find out whether constitutive HSF1 affects mRNA levels of the MIC proteins, total 
RNA was isolated from transfected cells and used for quantitative RT-PCR. Besides MICA 
and MICB, also the mRNA levels of HSP70 were determined, a known target of HSF1 (Fig. 
12C). Irrespective of the plasmid used for transfection, there was no difference in MICA and 
MICB mRNA levels in transfected cells compared to non-transfected control cells. On the 
other hand, both pHβAPr-hHSF1ΔRD and pLNCX2-hHSF1ΔRD strongly stimulated HSP70 
mRNA expression, suggesting that active HSF1 encoded by vectors was functional. 
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* Figure 12. Influence of active HSF1 on the expression of endogenous MIC molecules 
Melanoma cell lines UKRV-Mel-02 and MA-Mel-47 were transfected either with HSF1 
expression plasmids (pHβAPr-hHSF1ΔRD, pLNCX2-hHSF1ΔRD) or empty control plasmids 
(pHβAPr-1-neo, pLNCX2), or left untreated. Twenty-four hrs after transfection, cells were harvested 
and analyzed for the surface expression of MIC molecules, total MICB protein and MICA, MICB and 
HSP70 mRNA levels. Representative results from one of two independent experiments are depicted. 
A. Cells transfected with HSF1 expression plasmids or with control plasmids (black lines) or left 
untransfected (gray shaded histograms) were stained with unconjugated mouse anti-MICA and anti-
MICB mAb followed by PE-conjugated goat F(ab’)2 anti-mouse IgG and analyzed by flow cytometry 
for MIC surface expression. Light gray lines – background staining with the secondary PE–conjugated 
antibody only. 
B. Cells were harvested for whole cell lysate preparation. Proteins were analyzed by Western blot 
for the expression of total MICB protein. Control cells were left untransfected (first line – Nt). 
GAPDH was used as the loading control. 
C. Quantitative RT-PCR analysis of MICA, MICB and HSP70 mRNA expression in total RNA 
isolated from transfected cells. Expression levels form nontransfected control cells (NT) is set to one. 
Ct values of MICA and MICB were normalized to GAPDH Ct values. PCR reactions were performed 
in triplicates, error bars indicate SD. One representative experiment of two experiments for each cell 
line is presented. 
4.5.3 HSF1 silencing interferes with MICB induction under proteasome inhibition 
Site-directed mutagenesis of the HSE sequence within the MICB promoter region led to 
the loss of MICB promoter responsiveness to proteotoxic stress induced by MG132 treatment 
of the cells. As HSE is the conserved binding site for activated HSF1 this suggests that HSF1 
is essential for MICB up-regulation under proteasome inhibition. Although, expression of 
constitutive active HSF1 failed to induce endogenous MICB it strongly stimulated plasmid-
based reporter gene expression driven by the MICB promoter. In order to demonstrate the 
functional relevance of HSF1 for MICB up-regulation under proteasome inhibition a transient 
knock-down of HSF1 in melanoma cells with specific siRNA was performed.  
As shown at the Fig. 13, in both cell lines HSF1 was effectively silenced by siRNA 
HSF1 while control siRNA LUC did not affect HSF1 expression. Followed by siRNA 
transfection, cells were treated with MG132 and whole cell lysates were analyzed by Western 
blot for total MICB expression. In untransfected control cells as well as in cells transfected 
with siRNA LUC, treatment with proteasome inhibitor MG132 strongly enhanced MICB 
protein levels as compared to the untreated cells. Silencing of HSF1 led to a complete 
abrogation of MICB induction in UKRV-Mel-02 cells and strongly impaired MICB increase 
in MA-Mel-47 cells upon proteasome inhibition. The deregulated MICB response to MG132 
treatment in cells with an HSF1 knock-down clearly demonstrates the requirement of this 
transcription factor for the induction of MICB expression under this kind of stress. 
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Figure 13. Influence of HSF1 silencing on MICB expression 
Melanoma cell lines UKRV-Mel-02 and MA-Mel-47 were transfected with siRNA against HSF1, 
or with control siRNA LUC, or left untransfected. Fourty-eight hrs after transfection, cells were 
treated with 10 µM MG132, or with DMSO (solvent control) for 8 hrs, then harvested and used for 
whole cell lysate preparations. Lysates were analyzed by Western blot for the level of HSF1 and 
MICB protein. GAPDH served as loading control. The results are from one representative of three 
independent experiments. 
4.5.4 Interaction of HSF1 with the MICB promoter is epigenetically regulated 
Our results show that HSF1 is essential for MICB upregulation in melanoma cells under 
MG132 treatment. However, expression of a constitutive active HSF1 variant in melanoma 
cells only stimulated the activity of the plasmid-located but not of the endogenous cellular 
MICB promoter. This suggest that induction of MICB expression under proteasome inhibition 
is more complex and not just dependent on the activation of HSF1. Furthermore it suggests 
that the endogenous MICB promoter might be epigenetically closed. Ubiquitinated histone 
H2A (uH2A) has been described to act as a repressor of transcription. This repression is 
released upon deubiquitination of H2A (Zhou et al., 2008). Interestingly, inhibition of the 
proteasome has been described to elicit a very fast uH2A deubiquitination by depletion of the 
pool of free ubiquitin in the cell (Dantuma et al., 2006).  
Inhibition of the proteasome in UKRV-Mel-02 and Ma-Mel-47 cells led to the 
enrichment of polyubiquitinated proteins, as demonstrated by a Western blot (Fig. 14). 
Importantly, MG132 treatment of melanoma cells was also found to rapidly deplete uH2A (25 
kD), already 0.5 hrs after the onset of proteasome inhibition. No uH2A was detectable after 4 
hrs of treatment (Fig. 14).  
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These results suggest that deubiquitination of uH2A upon proteasome inhibition might 
allow active HSF1 to access the MICB promoter and to enhance MICB transcription. To 
confirm that the MICB promoter is indeed regulated by uH2A, chromatin 
immunoprecipitation (ChIP) assays were performed. Chromatin from nuclear pellets of MA-
Mel-47 cells, previously showing the strongest response to proteasome inhibitor treatment, 
was immunoprecipitated by anti-uH2A and anti-HSF1 antibodies and bound DNA was further 
analyzed by PCR using primer sets flanking different regions of the MICB promoter 
(Fig.15A). The ChIP analysis demonstrated an enhanced HSF1 recruitment to the MICB 
promoter under MG132 treatment. At the same time, proteasome inhibition decreased the 
level of uH2A at the MICB promoter, caused by the deubiquitination of the latter (Fig. 14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Proteasome inhibition leads to a rapid depletion of free ubiquitin and 
deubiquitination of monoubiquitinated H2A 
UKRV-Mel-02 and MA-Mel-47 cells were treated with MG132 (20 µM) for 0.5 and 4 hrs, or with 
DMSO (solvent control) for 4 hrs, then harvested and used either for total protein isolation or for 
histone acid extraction. Total protein was separated by SDS-PAGE and probed with anti-ubiquitin 
polyclonal Ab (FK2) recognising both monoubiquitin and polyubiquitin chains (top). Acid histone 
extracts were separated by SDS-PAGE and probed with anti-H2A polyclonal Ab, recognising both 
uH2A and H2A, yielding the bands of 25 and 14 kD, respectively (middle). GAPDH was used as the 
loading control (bottom). The results are representative on of two independent experiments. 
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Figure 15. Decrease of uH2A but increase of HSF1 levels at the MICB promoter under 
proteasome inhibition 
A. Schematic representation of the MICB promoter region and the primers used in ChIP 
experiments. 
B–C. MA-Mel-47 cells were treated with MG132 (20 µM) for 4 hrs or with DMSO (solvent 
control), then fixed, harvested and used for isolation of chromatin. Chromatin was immunoprecipitated 
by (B) anti-human uH2A and (C) anti-human HSF1 antibodies. Control antibodies used in ChIP 
experiments: mouse IgG; rabbit IgG anti-mouse IgM. Immunoprecipitated DNA was amplified by 
PCR using the indicated primer pairs, yielding the fragments ChIP1 and ChIP2. DNA input 
corresponds to non-immunoprecipitated chromatin. The data are representative from one of two 
independent experiments. 
 
Taken together, the MICB promoter is bound to uH2A under normal conditions 
restricting MICB transcription. Proteotoxic stress facilitates uH2A deubiquitination which 
increases the accessibility of the MICB promoter for transcription factors. The released 
promoter in turn can be bound by transcription factors such as HSF1, which subsequently 
leads to an enhancement of transcription. This represents another aspect in the complexity of 
the MICB regulation.  
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4.6 Proteasome inhibition stabilizes the surface expression of MIC molecules 
Monoubiquitination of transmembrane proteins is also known as a signal that controls 
endocytosis. MIC molecules are transmembrane proteins, of which most alleles contain three 
lysine residues in their cytoplasmic domain. It has been demonstrated that viral ubiquitin 
ligases mediate ubiquitination of these lysine residues thereby inducing the internalization of 
MIC molecules (Thomas et al., 2008). Similar to viral ligases also cellular ligases might be 
involved in the control of MIC internalization and their activity might also be influenced by 
depletion of free ubiquitin under proteasome inhibition. On the other hand, proteasome 
inhibition might prolong the membrane residence time of the MIC molecules by blocking the 
degradation of endocytosed proteins which then recycle back to the membrane. To investigate 
the stabilizing effect of MG132 on MIC surface expression, melanoma cells were treated with 
Brefeldin A (BFA), a potent inhibitor of protein transport from the ER to the Golgi. The 
treatment of melanoma cells with BFA alone led to a tremendous down-regulation of MICA 
surface expression within 8 hrs, also MICB was no longer detectable on the cell surface (Fig. 
16). The presence of MG132 rescued the surface expression of MICA and MICB in both 
melanoma cell lines. This indicates that proteasome inhibition also influence the surface 
expression of MIC molecules. The underlying mechanism remains to be elucidated and was 
beyond the scope of the thesis. 	   
 
 
 
 
 
 
 
 
 
Figure 16. MG132 stabilizes MIC molecules on the cell surface 
UKRV-Mel-02 and MA-Mel-47 cells were incubated with 10 µM MG132 (black lines – top), 5 
µg/ml BFA (black lines – middle), or with MG132 and BFA (black lines – bottom) simultaneously for 
8 hrs and then analyzed for MICA, MICB and HLA class I surface expression by flow cytometry. 
Control cells were treated with the solvent DMSO (shaded histograms). Gray lines – background 
staining with the secondary PE–conjugated antibody only. The results are representative from one of 
the three independent experiments. 
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5 Discussion 
Malignant melanoma is one of the most aggressive tumors, with a persistently rising 
incidence rate over the last decades. The metastatic tumor displays a marked resistance to 
conventional cytotoxic drugs resulting in disappointing clinical outcomes when currently 
available chemotherapeutic treatment strategies are used (Soengas et al., 2003; Chin et al., 
2006). In principle, the patient’s immune system has the capability to recognize and kill tumor 
cells. Several melanoma-associated antigens have been characterized which are recognized by 
cytotoxic CD8+ T cells in the complex with surface MHC class I molecules. Recently, a 
number of clinical studies have demonstrated specific interaction and effective eradication of 
melanoma cells by adoptively transferred T cells (Straten and Becker, 2009). Thus, 
immunotherapy might be a promising alternative strategy for the treatment of malignant 
melanoma. 
However, during progression melanoma cells can down-regulate or completely loose 
MHC class I expression, which interferes with the effective recognition and eradication of the 
tumor cells by T cells. In our lab it was demonstrated that the loss of MHC class I expression 
in melanoma metastases is generally due to mutations in the gene encoding β2-microglobulin, 
which is part of the MHC class I complex (Paschen et al., 2003; 2006). Loss of MHC class I 
molecules allows melanoma cells to escape immune surveillance by T cells, but at the same 
time, according to the “missing self” theory, those tumor cells become targets for NK cells, 
given that they express ligands for activating receptors of NK cells on their surface. If 
activatory ligands are not present on the tumor cell, effective recognition and elimination by 
NK cells cannot take place. Recently, a number of activating receptors on NK cells have been 
described (reviewed by Eagle and Trowsdale, 2007; López-Larrea et al., 2008). One of the 
key receptors in the anti-tumor activity of NK cells is the C-type lectin-like molecule NKG2D 
triggering cytokine as well as perforine and granzyme release. In fact, it has been shown that 
NKG2D contributes to the early recognition and elimination of tumors by NK cells and 
knock-down of the expression of this receptor in mice yielded an increased incidence of 
spontaneous tumors (Guerra et al., 2008).  
In humans, NKG2D is expressed on NK cells, some NKT cells and CD8+ T cells 
(Champsaur and Lanier, 2010). On activated NK cells it functions as a main activating 
receptor, while on T cells NKG2D mostly plays a co-stimulatory role. Once bound to its 
surface ligand on a target cell the NKG2D receptor delivers activating signals into an effector 
cell. So far eight NKG2DL have been identified in human: MICA, MICB, ULBP1-6. The 
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present study focused on the analysis of MICA and MICB expression and the differences in 
their regulation under proteotoxic stress caused by proteasome inhibition. 
5.1 In situ expression and shedding of NKG2D ligands  
NKG2DL are stress molecules, which are commonly found to be restricted under 
normal conditions in vivo, thereby preserving normal cells from the recognition and 
elimination by NK cells and certain T cells. However, NKG2DL expression has also been 
reported on some cells that could not be described as stressed or damaged. For example 
activated T cells can express NKG2DL, and constitutive expression of NKG2DL has been 
reported on normal myelomonocytic cells, dendritic cells, and epithelial cells of the gut 
mucosa (reviewed by Eagle et al, 2009), suggesting that NK cells can play a role in the 
regulation of inflammatory responses preventing the persistent over-activation of CD8+ T 
cells via their direct killing, or killing of helper cells, such as antigen-presenting cells. T 
regulatory cells (Tregs) have also been shown to be targets for NK cells, though their 
elimination by NK cells might be regulated via NKG2DL-independent mechanism. NKG2DL 
expression on epithelial cells in the gut or airways might be explained by the fact that these 
cells have to be often renewed due to their guardian function as a barrier for pathogens (Eagle 
et al., 2009). 
Many tumor cell lines and freshly isolated primary tumors express NKG2DL. Tumor 
cells extracted from patients with different types of leukemia, including AML, ALL, CML, 
and CLL, express heterogeneous levels of NKG2DL (Salih et al., 2003). In addition, using the 
human NK cell line NKL as effector cells it was shown that expression of NKG2DL on 
patient AML and CML cells rendered them susceptible to NK cell mediated lysis in an 
NKG2D-dependent manner. MICA and MICB are expressed in a subset of human 
hepatocellular carcinoma tissues and are involved in hepatoma cell sensitivity to NK cell 
killing in vitro (Armeanu et al., 2008). Primary glioma cultures as well as glioma cell lines 
display surface NKG2DL expression (Friese et al., 2003). In colorectal cancer high levels of 
MICA in situ are associated with a good prognosis (Watson et al., 2006).  
Human melanoma cells can express NKG2DL in situ (Vetter et al., 2002; Paschen et al., 
2009), but NKG2DL expression has been described to be lost during the progression of uveal 
melanoma (Vetter et al., 2004). In our lab it was shown that melanoma cells cultured in vitro 
as well as tumors in situ show expression of MICA and ULBP2, though expression of the 
ligands within metastatic tumors was often very heterogeneous. Melanoma cells were 
effectively recognized and lysed by NKL cells in an NKG2D-dependent manner. Blocking of 
the NKG2D receptor led to an impaired lysis of melanoma cells in vitro (Paschen et al., 2009; 
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Schwinn et al., 2009). Immunohistochemistry analyses on tumor metastases, controlled by 
staining against HMB-45 a melanoma-associated antigen, demonstrated that expression of 
NKG2DL within the lesions varied and in some tumors MIC-positive cells were primarily 
located at the periphery of the tumor. This suggests that in situ expression of NKG2DL in the 
melanoma could be influenced by the microenvironment, by cell-cell contacts as well as by 
soluble factors like cytokines (Paschen et al., 2009; Schwinn et al., 2009). Another 
explanation for the low level of NKG2DL expression is situ might has been suggested to be 
their proteolytic shedding (Salih et al., 2002). It has been shown that decreased levels of 
MICA on gastrointestinal tumor cell lines were due to the activity of extracellular matrix 
metalloproteinases (MMPs). The blocking of proteinases by MMP inhibitors resulted in a 
reduced ligand release and sustained surface expression of MICA. NKG2DL shed by tumor 
cells become detectable in patient sera, thus, the levels of soluble MICA were significantly 
higher in sera of patients with gastrointestinal malignancies as compared to sera of healthy 
donors (Salih et al., 2002). Recently it has been shown that NKG2DL shedding in advanced 
diseases also has “clinical significance”. Our group has demonstrated that enhanced levels of 
sNKG2DL can be detected in sera of melanoma patients which were associated with poor 
prognosis (Paschen et al., 2009). The soluble forms of NKG2DL are still able to bind to the 
NKG2D receptor thereby causing persistent activation of NK cells, which in turn leads to the 
internalization of NKG2D and reduced reactivity of NK cells against the tumor cells. Hence, 
the poor prognosis associated with NKG2D ligand release might on the one hand be due to a 
decrease in melanoma immunogenicity but on the other hand, might also be supported by an 
impaired NK cell activity. These observations suggest that therapeutic up-regulation of 
NKG2DL expression might be a promising strategy to increase immunogenicity of 
melanoma. 
5.2 Signals controlling expression of NKG2D ligands  
At present the regulation of NKG2DL is intensively studied. A number of different 
stresses inducing NKG2DL expression on the cell surface have been described. It has been 
also shown that depending on the type of the stress, different ligands are induced. Viral 
infection induces expression of NKG2DL, but exact mechanism of this induction is for most 
part unknown. Viral proteins can either directly affect NKG2DL transcription (Venkataraman 
et al., 2007), or the release of cytokines upon infection can indirectly control NKG2DL 
expression (Cerwenka and Lanier, 2001; Champsaur and Lainier, 2010). Some viruses like 
mouse and human CMV evolved mechanisms to retain NKG2DL in the cell and to prevent 
their surface expression	  (Dunn et al., 2003; Thomas et al., 2008).  
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Different cytokines, in particular interferons, have been described to control NKG2DL 
expression. Our own studies revealed a STAT1-dependent down-regulation of MICA in 
human melanoma under IFN-γ treatment (Schwinn et al., 2009), while on monocytes IFN-γ 
has been demonstrated to induce MIC expression (Wang et al., 2009), suggesting that the 
cellular context might influence the outcome of NKG2DL expression.  
Up-regulation of MICA and MICB ligands has been reported under oxidative stress and 
heat shock stress in human colon carcinoma cells HCT116 (Venkataraman et al., 2007), 
Oxidative stress can induce DNA damage. Indeed, DNA damage has been described to cause 
an up-regulation of NKG2DL via ATM and ATR dependent mechanisms. Gasser et al. 
demonstrated that ionizing irradiation of secondary human foreskin fibroblasts stimulated 
ULBP1, 2 and 3 as well as MICA expression via ATM/ATR, which sense DNA double-strand 
breaks and stalled DNA replication, respectively, resulting in cell cycle arrest, DNA repair or 
apoptosis (Gasser et al., 2005).  
5.3 Proteasome inhibiton induces expression of NKG2D ligands on tumor 
cells 
Within the present study the influence of proteasome inhibition on NKG2DL expression 
in melanoma cells was analyzed. Proteasome inhibitors are currently tested as small 
therapeutic molecules for the treatment of different tumor entities, including melanoma 
(Russo et al., 2010; Su et al., 2010). As the proteasome is the major cellular proteolytic 
machinery, drugs blocking its activity cause an accumulation of polyubiquitinated proteins in 
the cytosol, the nucleus and induce an ER associated degradation stop (Adams, 2004). The 
signals elicited by proteasome inhibitors in tumor cells are multifaceted. Proteasome 
inhibitors are shown to induce apoptosis in highly proliferating tumor cells, which have a 
robust protein turn-over, while less affecting normal, quiescent cells (Almond and Cohen, 
2002). Proteasome blockade suppresses the NF-κB pathway preventing digestion of the 
inhibitory subunit IκB, leading to cell cycle arrest. (Chauhan et al., 2005). Moreover, 
blockade of proteasome function activates caspases as well as pro-apoptotic proteins such as 
BH3-only proteins and PUMA triggering apoptosis via the p53/PUMA pathway (Concannon 
et al., 2006). 
In the present study we demonstrated that treatment of human melanoma cells with 
proteasome inhibitors led to an up-regulation of NKG2DL expression. We found that 
proteotoxic stress induced upon proteasome inhibition strongly stimulated MICB expression 
in melanoma cells via direct activation of the MICB promoter. In addition to that prolonged 
proteotoxic stress was able to induce surface expression of MICA and ULBP2, though, this 
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up-regulation was considered to be the result of complex secondary effects. Under the 
conditions tested we observed an induction of NKG2DL on MHC class I-negative and MHC 
class I-positive tumor cells, while the surface expression of MHC class I molecules, as 
measured by flow cytometry, was not affected. Thus, by inducing NKG2DL expression on 
MHC class I-negative and MHC class I-positive melanoma cells, proteasome inhibitors may 
facilitate target cell recognition and killing by NK cells and CD8+ T cells, respectively. 
Indeed, Armeanu et al. demonstrated an increased recognition of proteasome inhibitor treated 
HCC cells by NK cells that was mediated by the NKG2D receptor (Armeanu et al., 2008). 
They observed that low-dose bortezomib and other proteasome inhibitor drugs caused human 
hepatocellular carcinoma cell lines to produce increased amounts of MICA and MICB, while 
ULBP1–3 remained uninfluenced. Butler et al., 2009 studied the influence of proteasome 
inhibition on HNSCC cells and observed that the cells responded via up-regulation of ULBP1 
surface expression, which increased tumor cell recognition by NK cells. The authors 
demonstrated that this upregulation occurs via an ATM/ATR independent pathway. In 
contrast, Valés-Gómez et al. reported that exposure of Jurkat cells to very low concentrations 
of MG132 selectively induced expression ULBP2 (Valés-Gómez et al., 2008). They 
suggested that ATM and ATR, which are normally described to be involved in the DNA 
damage pathway, are required for ULBP2 expression after proteasome inhibition. Taken 
together, these studies demonstrate that proteasome inhibitors act differently on NKG2DL, 
most probably dependent on the cell type, on the dose and time of the treatment. 
Besides killing by NK cells, proteasome inhibition has also been demonstrated to 
increase the sensitivity of melanoma cells to lysis by T cells by enhancing the mitochondrial 
apoptotic response, which causes mitochondrial accumulation of NOXA. As a consequence 
the release of the second mitochondria-derived activator of caspase (SMAC) occurs, which is 
suggested to be responsible for the sensitization (Seeger et al., 2010).  
5.4 Transcriptional and post-transcriptional regulation of MIC expression 
Within this study and previous work, it was demonstrated that of the MIC molecules, 
MICA was predominantly expressed on the surface of melanoma cell lines, while MICB 
expression was frequently undetectable or occurred only at very low levels (Schwinn et al., 
2009). The disparity in MICA and MICB expression may be accounted for by diverse 
regulatory mechanisms acting on different levels of expression such as transcription, mRNA 
stability or translation. Recently, the promoter region of both the MICA and MICB gene was 
analyzed and binding sites of specific transcription factors were defined (Eagle et al., 2006; 
Venkataraman et al., 2007; Rodriges-Rodero et al., 2007). A number of DNA elements 
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essential for MIC transcription and stress-mediated activation of the promoter were described, 
such as TATA-like elements, Sp1 sites and a heat shock responsive element (HSE). Sp1 
binding sites (GC-islands) and TATA-box have been shown to be essential for expression of 
MICA and MICB in HCT 116 cells (Venkataraman et al., 2007).  
One of the possible reasons for the differences in MICB expression levels between cell 
lines might be the fact that the MICB promoter is highly polymorphic. In some alleles single 
nucleotide polymorphisms within or in close proximity of binding sites have been identified, 
which may interfere with an efficient Sp1 binding, thereby influencing MICB expression 
(Rodríges-Rodero et al., 2007).  
Post-transcriptional mechanisms have been shown to control NKG2DL expression. A 
number of human microRNAs have been identified by Stern-Ginossar et al. collectively 
regulating MICA and MICB expression (Stern-Ginossar et al., 2008). Based on their data the 
authors suggested that these microRNAs set up a threshold to prevent the expression of MICA 
and MICB proteins and consequently the killing of healthy self cells. During short-term 
stresses, such as heat shock and viral infection, although microRNA amounts do not change 
much, higher MICA and MICB mRNA expression stimulated by stress may “saturate” the 
microRNA suppressive capacity and, ultimately, result in MICA and MICB protein 
expression. MICB has a fivefold longer 3’ untranslated region (3’ UTR) than MICA, which 
may have other so far not identified seed sequences for microRNAs distinct from those 
targeting MICA 3’ UTR and retaining MICB translation.  
The discrete patterns of MICA and MICB expression might be also caused by epigenetic 
regulation. In fact, we found that in melanoma cells the MICB promoter region is bound to 
mono-ubiquitinated histone H2A operating as a gene expression silencer and proteotoxic 
stress facilitates the release of the MICB promoter region from this repression. The 
mechanism of this regulation will be discussed below. 
5.4.1 HSF-1 dependent induction of MICB expression upon proteasome inhibition   
According to our data short-term proteasome inhibitor drug treatment caused a strong 
up-regulation of MICB mRNA, while MICA and ULBP mRNA levels were not significantly 
influenced. The combined treatment of melanoma cells with Actinomycin D, which is an 
inhibitor of transcription and proteasome inhibitor, abrogated the induction of MICB mRNA, 
suggesting that transcription is essential for the up-regulation of MICB mRNA under 
proteotoxic stress, and that stabilization of mRNA is not a major event. We have found that 
the treatment with MG132 was able to activate the MICB promoter. To better understand the 
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mechanism and to define the factors responsible for transcriptional stimulation under 
proteasome inhibition, several MICB promoter constructs were generated. The longest 
promoter fragment consisted of 470 bp upstream of the start codon and contained a known 
HSE sequence and a putative binding site for NRF1. A second fragment of 225 bp contained 
only the HSE, while the shortest promoter fragment (115 bp) lacked this element. As control 
the MICA promoter construct of 455 bp was generated. Promoters were cloned into pGL4.10 
a promoterless vector, upstream of the Firefly luciferase gene. The first promoter construct 
and the second one, containing HSE, were strongly activated when proteotoxic stress was 
applied. The shortest MICB promoter failed to drive luciferase gene expression in melanoma 
cells both under normal culture conditions and under proteotoxic stress. 
Proteasome inhibitors have been also reported to cause a heat shock response (Bush et al 
1997). We proposed that proteotoxic stress may activate HSF1, which is a member of the heat 
shock transcription factor family regulating heat shock genes. The heat shock response is an 
evolutionary conserved process, which defends the organism from environmental stress. It is 
very rapid and mostly acts on heat shock responsive genes via induction of transcription, but 
not mRNA stabilization (Shamovsky and Nudler, 2008). Heat shock responses are executed 
by heat shock transcription factors, such as HSF1 and HSF2. The latter has been mainly 
reported to participate in development, but recently growing body of evidence suggests that it 
is capable to cooperate with the key player of the heat shock response, with HSF1 
(Shamovsky and Nudler, 2008). Transcription factor HSF1 is constitutively expressed in the 
cell under the normal conditions and where it is present both in the cytoplasma and in the 
nucleus in an inactive form. It is known to form inhibitory complexes with HSP70/HSP40, 
but the main negative regulator of HSF1 is believed to be the abundant chaperon HSP90. Heat 
shock stress rapidly converts HSF1 to its active form via post-translational modifications. 
HSF1 is released from complexes with chaperones, becomes phosphorylated and activated. 
The activation event is associated with the transition of the monomer form to a trimer, which 
acquires a strong DNA-binding activity (Shamovsky and Nudler, 2008). HSF1 trimers bind to 
an extremely conserved sequence, the heat shock responsive element (HSE), which is present 
within promoter region of heat shock responsive genes. Interestingly, a number of different 
stressors, such as hypoxia, peroxides, alcohols, and transition metal ions, leading to an 
accumulation of proteins, operate via the heat shock responsive machinery (Shamovsky and 
Nudler, 2008). 
To analyze the role of HSF1 in the induction of MICB promoter activity, site-directed 
mutagenesis of the HSE sequence within the MICB promoter was performed. HSE mutation 
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led to a loss of promoter responsiveness under proteotoxic stress pointing out the essential 
role of HSE and HSF1 in the implication of a stress response. Moreover, Fionda et al. showed 
that the inhibition of HSP90, a negative regulator of HSF1, led to the rapid activation of the 
latter and also stimulated transcription and surface expression of MICA and MICB in multiple 
myeloma cells and sensitizing them to NK cell recognition (Fionda et al., 2009). The next step 
to make sure that HSF1 is the key factor triggering MICB up-regulation under proteotoxic 
stress was to knockdown its expression by siRNA. Indeed, cells with silenced HSF1 did not 
respond to proteotoxic stress and did not up-regulate MICB protein expression as compared to 
the cells transfected with control siRNA or to non-transfected cells. Taken together, the data 
underline the essential role of HSF1 in the regulation of MICB expression by proteasome 
inhibition. In accordance to our study, Venkataraman et al. demonstrated that the HSE 
element is important to induce MIC expression under heat shock (Venkataraman et al., 2007). 
In order to confirm the essential role of HSF1 in the regulation of MICB expression in 
response to proteotoxic stress induced by MG132 treatment we over-expressed a constitutive 
active HSF1 in melanoma cells by transient transfection. Expression of active HSF1 in cells 
co-transfected with MIC promoter constructs led to a strong induction of both MICA and 
MICB promoter activity, while co-transfection of empty control vectors with MICA and 
MICB promoter constructs did not cause their activation. However, transient expression of 
active HSF1 did not influence the endogenous MIC expression of the cell. Surface expression, 
total protein level as well as mRNA level of MIC molecules remained unchanged after the 
transfection of melanoma cells with plasmids encoding constitutively active HSF1, while 
HSP70 mRNA, a direct target of HSF1, was strongly increased, which confirms functional 
activity of HSF1. We suggest that activated HSF1 can only get the access to the endogenous 
cellular MICB promoter, when the promoter region is opened by additional regulatory events. 
Thus, the MICB promoter might be epigenetically silenced in the absence of proteotoxic 
stress induced by proteasome inhibition. 
5.4.2 Depletion of free ubiquitin under proteasome inhibition influences MICB expression 
Within this study it has been shown that proteotoxic stress strongly increased MICB 
expression. We speculated that blockade of the proteasome may lead to a depletion of the free 
ubiquitin pool in the cell because of a blockade in ubiquitin turn-over.  
Free ubiquitin is important to maintain the ubiquitination of histones such as H2A. DNA 
is organized in a compact chromatin structure consisting of nucleosoms controlling DNA 
accessibility. A nucleosome is composed of four histones H2A, H2B, H3 and H4, which are 
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organized in octamers and consists of 147 bp DNA wrapped around each octamer. The 
structure is very stable because of the multiple interactions of DNA and histones, which 
prevents unnecessary transcription. Accessibility of DNA to factors initiating transcription 
can be controlled by a number of different covalent modifications of histones, which can in 
turn either facilitate or repress transcription. So far, the following histone modifications have 
been identified: acetylation, methylation, monoubiquitynation, sumoylation, ADP-
ribosylation and phosphorylation (Li et al., 2007). Mostly, histone modifications have been 
mapped to the upstream region of the core promoter, the 5’ or the 3’ region of the open 
reading frames of the genes. The modifications, which silence genes or chromosome regions, 
are found predominantly in the heterochromatin. On the contrary, the modifications 
facilitating transcription localize in euchromatin regions. This system is able to fine tune gene 
transcription. In most cases covalent modifications result in a change of the nucleosome 
charge that could loosen DNA-histone association. Moreover, histone modifications can be 
recognized by other proteins influencing chromatin dynamics and function like chromatin 
remodeling enzymes or transcription factor complexes, which can even displace histone 
dimers of H2A and H2B, or the entire octamer (Li et al., 2007). 
One of the most important modifications is histone monoubiquitynation. So far only 
H2A and H2B have been described to be ubiquitinated. The ubiquitination process is well 
characterized and consists of three steps. Ubiquitin is first activated by an ATP-dependent 
reaction involving a ubiquitin activating enzyme (E1), followed by its conjugation via a 
thioester bond to a cysteine residue in a ubiquitin-conjugating enzyme (E2). In the final 
enzymatic step, ubiquitin is transferred from the E2 enzyme to a target lysine residue in a 
particular substrate protein by an ubiquitin-protein isopeptide ligase (E3). E3 enzymes are 
often characterized by the presence of a C3HC4 (RING) finger motif, which binds zinc and is 
required for ubiquitin ligase activity (Weake et al., 2008). To date, a number of histone Ub-
ligases have been identified. In mammals histone H2B is monoubiquitynated at lysine 120 by 
the E3 ubiquitin ligase hBRE1 or RNF20/RNF40 (Zhu et al., 2005). Only 1% of H2B has 
been fount to be monoubiquitynated and its function has been related to transcription 
initiation. H2A ubiquitination that occurs at lysine 119 has been estimated to comprise 
between 5% and 15% of the available H2A and is a relatively abundant modification. While 
some studies have pointed to an association of uH2A with transcriptionally active chromatin 
(Nickel et al., 1989), others have failed to demonstrate this (Kallin et al., 2009). Recent 
studies show that RING2/Ring1b in the Polycomb repressive complex 1 (PRC1) 
monoubiquitynates nucleosomal histone H2A at lysine 119 and links H2A ubiquitination to 
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Polycomb silencing (Wang et al., 2004) as well as to X chromosome inactivation (de Napoles 
et al., 2004). More recent studies suggested that both Ring1A and another component of 
PRC1, Bmi-1, play an important role in H2A ubiquitination and Hox gene silencing and 
demonstrate the sequential events of H3-K27 methylation by methyltransferase EZH2 and 
H2A-K119 ubiquitination (Cao et al., 2005). Although, the mechanism of H2A ubiquitination 
leading to gene repression is mostly unknown, there are evidences that histone H2A 
monoubiquitination represses transcription of the RANTES gene via blocking of FACT 
(facilitates transcription) complex recruitment to the promoter region of the gene (Zhou et al., 
2008). We found that the MICB promoter is associated with monoubiquitinated histone H2A, 
which may block transcription initiation under normal conditions. This might explain why the 
constitutively active HSF1 (Nakai A, Widlak W, see Materials) failed to stimulate 
endogenous MICB expression in transfected melanoma cells. The situation is different when 
cells were co-transfected with HSF1 and opened-structured MICB promoter reporter gene 
constructs. In this case HSF1 could easily access the MICB promoter and stimulate 
transcription of the luciferase reporter gene.  
During proteotoxic stress caused by proteasome inhibition, the accumulation of 
ubiquitinated substrates takes place, which in turn leads to the depletion of the free ubiquitin 
pool. Dantuma et al. showed that this coincides with the depletion of ubiquitinated histone 
H2A and chromatin remodeling (Dantuma et al., 2006). Proteasome inhibition does not alter 
the rate of histone deubiquitination, but depletes the pool of free ubiquitin, which may result 
in a rising competition between ubiquitin substrates – proteasome substrates and histones. 
This assumption was confirmed for melanoma cells. When treated with proteasome inhibitor 
for 4 hrs the level of ubiqutinantion of H2A at the MICB promoter clearly decreased. 
Depletion of free ubiquitin under MG132 treatment is reflected in a decrease of H2A 
ubiquitination, the subsequent release of the promoter DNA for transcription factor binding. 
We also demonstrated that under proteotoxic stress binding of HSF1 to the MICB promoter 
region is enhanced. However, in the absence of proteotoxic stress the MICB promoter region 
seems not to be locked in a way that prevents efficient binding of HSF1 (Venkataraman et al., 
2007; Rodríguez-Rodero et al., 2007). 
5.4.3 Stabilisation of MIC surface expression under proteasome inhibition 
We confirmed that inhibition of translation via Cycloheximide treatment led to a rapid 
reduction of total MIC protein levels, pointing out that MIC molecules are short-lived 
proteins. It has been described that most MICA and MICB alleles encode proteins with a long 
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cytoplasmic domain containing a number of ubiquitination sites (lysines) located close to the 
transmembrane domain of the proteins (Thomas et al., 2008). This seems to be important for 
the internalization of the proteins and the redistribution in intracellular compartments. In 
general, the regulation of the membrane residence of stress markers like MIC molecules is 
extremely important as the long presence of the stress ligands at the cell surface might be 
harmful for the cells and lead to autoimmune disturbances.  
Interestingly, some viruses such as the Kaposi sarcoma associated herpes virus evolved 
mechanisms to escape NK cell surveillance by down-regulating NKG2DL from the surface of 
virus-infected cells. The viral genome encodes the ubiquitin ligase K5, which has been shown 
to ubiquitinate the lysine residues of the cytoplasmic domain of the MIC molecules, leading to 
their rapid internalization. Moreover, K5 failed to retain the surface expression of MICA*008 
with a truncated cytoplasmic domain lacking ubiquitination sites (Thomas et al., 2008).  
Also cellular ubiquitin ligases exist that are involved in the regulation of the membrane 
persistence of proteins (Lehner et al., 2005) and that trigger internalization of transmembrane 
molecules by mono- or diubiquitination of lysine residues within the cytoplasmic domains. 
Thus, we speculated that the activity of such ligases might be disturbed also by depletion of 
the free ubiquitin pool upon proteasome inhibition. To analyse this melanoma cells were 
treated with Brefeldin A (BFA), an inhibitor of the vesicular transport from the Golgi to the 
surface membrane and BFA in combinantion with MG132. Blocking by BFA strongly 
interfered with the surface expression of both MICA and MICB suggesting that trafficking 
through the cellular compartment is relevant for an effective surface expression. Thus, 
blocking of the vesicular transport interrupts the delivery of the newly synthesized NKG2DL 
to the cell surface. BFA treatment together with proteasome inhibition stabilized MICA and 
MICB molecues on the melanoma cell lines studied. Hence, we suggest that inhibition of the 
proteasome might stabilize MIC molecules at the cell surface via abrogation of endocytosis. 
On the other hand, proteasome inhibition might prolong the membrane residence time of the 
MIC molecules by blocking the degradation of endocytosed proteins which then recycle back 
to the membrane. The exact mechanism facilitating the prolonged residence of MIC 
molecules on the cell surface under proteotoxic stress needs to be elucidated and was beyond 
the scope of the thesis. 
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6 Conclusions 
Taken together we found that proteotoxic stress elicited by inhibition of the proteasome 
strongly up-regulates MICB expression in human melanoma cells. The mechanism of this 
induction is rather complex and involves different levels of regulation such as transcriptional, 
epigenetic, and post-translational regulation. We first showed that proteasome inhibition 
intensively induces MICB transcription, which is mediated by HSF1. Silencing of HSF1 in 
vitro interfered with MICB up-regulation under proteotoxic stress as well as mutation of the 
HSF1 binding site (HSE) within the MICB promoter led to the abrogation of MICB promoter 
activation in cells incubated with a proteasome inhibitor. Over-expression of a constitutively 
active HSF1 in the melanoma cells was found to stimulate only the MICB promoter cloned in 
the reporter gene plasmids, but not the cellular endogenous MICB promoter, suggesting that 
other mechanisms controlling the accessibility of the MICB promoter for HSF1 have to be 
involved. We showed that the MICB promoter is associated with ubiquitinated histone H2A 
(uH2A), which is known to be involved in gene silencing. Proteasome inhibition resulted in a 
loss of H2A ubiquitination. Along with this we showed in CHIP experiments that proteasome 
inhibition decreased the levels of uH2A at the MICB promoter wile increasing the binding of 
HSF1 which in turn triggers MICB transcription. Moreover, we found that MG132 not only 
transcriptionally regulates MICB, but also prolongs the residence of MICB protein on 
melanoma cell surface.  
The uncovered mechanism might be relevant for novel melanoma treatment strategies 
including proteasome inhibitors not only as inducers of apoptosis and sensitizers of 
chemotherapy, but also as agents to modulate the immunogenicity of melanoma.  
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Figure A1. Annexin/PI staining of melanoma cells treated with proteasome inhibitor 
UKRV-Mel-02 and MA-Mel-47 cell lines were treated with 10 µM MG132 or with DMSO as a 
solvent control for 8 hrs, harvested and stained with APC-Annexin V and Propidium iodide (PI) to 
ascertain the fraction of the cells which undergo apoptosis (Annexin V /PI). “Gating” dotplots 
represent the strategy used to gate on living cells. Annexin V positive population represent cells 
undergoing apoptosis. Double positive populations represent dead cells. For both cell lines there was 
no significant difference in the number of cells, which undergo apoptosis, between controls or MG132 
treated cells. Data are representative of two independent experiments for each cell line.  
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A 
Ab  antibody 
ACT  adoptive cell transfer  
Act.D.  Actinomycin D 
ADP  adenosine 5’-diphosphate 
AKT  serine/threonine kinase B (PKB) 
ALL  acute lymphatic leukemia 
AML  acute myeloid leukemia  
ATM  ataxia telangiectasia, mutated 
ATR  ATM and Rad3-related 
ATP  adenosine 5’-trihosphate 
 
B 
Bcl  B-cell lymphoma 
BCR/ABL breakpoint cluster region/c-abl oncogene 1, non-receptor tyrosine kinase 
BFA  Brefeldin A 
bp  base pairs 
BPB  bromphenol blue 
B-RAF B-Raf proto-oncogene serine/threonine-protein kinase 
BSA  bovine serum albumin 
 
C 
CD  cluster of differentiation 
CDK4  cyclin dependent kinase 4 
CDKN2A cyclin-dependent kinase inhibitor 2A 
cDNA  coding DNA 
ChIP  chromatin immunoprecipitation 
CHX  Cycloheximide 
CML   chronic myeloid leukemia 
CMV  cytomegalovirus 
CLL   chronic lymphatic leukemia 
conc  concentration 
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Ct  threshold cycle by RT-PCR 
CTLA-4 cytotoxic T-lymphocyte antigen 4 
 
D 
DC  dendritic cell 
dNTP  deoxyribonucleotide triphosphate 
DMSO dimethyl sulfoxide 
DTIC  Dimethyl-trizeno-imidazol-Carboxamid (also called Dacarbazine) 
 
E 
ECL  enhanced chemiluminescence 
EDTA  ethylenediaminetetraacetic acid 
ER  endoplasmic reticulum 
ERK  extracellular-signal-regulated kinase 
 
F 
Fab  fragment antigen binding 
6-FAM 6-Carboxy->Fluorescein 
FACS  fluorescence activated cell sorting 
FACT  facilitates chromatin transcription 
FDA  U.S. Food and Drug Administration 
 
G 
g  gram 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
gp100  glycoprotein 100, a melanoma antigen 
GPI  glycosylphosphatidylinositol 
GTP  guanosine-5'-triphosphate 
 
H 
H2A  histone H2A 
HDAC  histone deacetylase 
HCC  hepatocellular carcinoma 
HLA  human leukocyte antigen 
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HNSCC head and neck squamous cell carcinoma 
HRP  horseradish peroxidase 
hrs  hours 
HSE  heat shock responsive element 
HSF1  heat shock factor 1 
HSP  heat shock protein 
HSV-TK herpes simplex virus thymidine kinase 
 
I 
IFN  interferon 
Ig  immunoglobulin  
IκB  IkappaB kinase, inhibitor of NF-kappaB kinase 
IL  interleukin 
 
K 
kb  kilobase 
kD  kilodalton 
KD   dissociation constant 
KIR  killer cell immunoglobulin-like receptor 
 
L 
l  liter 
LPS  lipopolysaccharides 
LUC  luciferase 
 
M 
µl  microliter 
µM  micromolar 
ml  milliliter 
mM  millimolar 
µg  microgram 
mg  milligram 
min  minute 
mAb  monoclonal antibody 
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MAPK mitogen activated protein kinase 
MDM2 negative regulator of p53, E3 ubiquitin ligase 
MEK  MAP-ERK kinase 
Melan-A/MART-1 Melanoma-associated antigen recognized by T cells  
MHC  major histocompatibility complex 
MICA/B MHC class I chain-related sequence A/B 
MIC  MICA and MICB 
miRNA microRNA 
MMP  matrix metalloproteinases 
mRNA messenger ribonucleic acid 
mTOR  mammalian target of rapamycin 
 
N 
NCR  natural cytotoxicity receptor 
NF-κB  nuclear factor kappa-B 
NK  Natural killer cell(s) 
NKG2D Natural-killer group 2, member D  
NKG2DL NKG2D ligand(s) 
NKT  Natural killer T cell(s) 
NOD/SCID Non-obese diabetic/severe immunodeficiency genetic disorder mice 
NOXA  phorbol-12-myristate-13-acetate-induced protein 1, a pro-apoptotic member of 
the Bcl-2 protein family 
NRAS  neuroblastoma RAS viral (v-ras) oncogene homolog 
NRF1  nuclear respiratory factor 1 
 
O – P 
OD  optical density 
p53  protein 53, a tumor suppressor 
PCR  polymerase chain reaction 
PE   phycoerythrin 
PFA  PBS/formaldehyde 
PI3K  phosphatidylinosytol 3-kinase 
PMSF  phenylmethylsulfonyl fluoride 
PRC  polycomb repressive complex 
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PTEN  phosphatase and tensin homolog 
PUMA  p53 upregulated modulator of apoptosis, a pro-apoptotic member of the Bcl-2 
protein family 
 
R 
Rae1  retinoic acid early inducible gene-1 
RAS  specific guanine nucleotide-releasing factor 1 
RING  really interesting new gene domain 
RNA Pol II RNA polymerase II 
rpm  rotations per minute 
RT  room temperature 
RT-PCR reverse transcription polymerase chain reaction 
 
S 
SD  standard deviation 
SDS  sodium dodecyl sulfate 
sNKG2DL soluble NKG2D ligand(s) 
siRNA  small interfering RNA 
SMAC  second mitochondria-derived activator of caspase 
STAT  signal transducer and activator of transcription 
SV40  Simian vacuolating virus 40 
 
T 
Taq Thermus aquaticus  
TBS  Tween/PBS 
TEB  triton extraction buffer 
TGF  transforming growth factor 
TLR  toll-like receptor 
TMZ  Temozolomide 
TNF  tumor necrosis factor 
TRAMP mouse prostate adenocarcinoma model 
TRIS  tris (hydroxymethyl) aminomethane 
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U 
Ub  ubiquitin 
uH2A  monoubiquitinated histone H2A 
ULBP  UL16-binding proteins 
UMP1  proteasome maturation protein 
UPS  ubiquitin-proteasome system 
UTR  untranslated region 
UV  ultraviolet 
 
W – Z 
WB  western blot 
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